Unnamed: 0,title,date,stock,sentiment
174091.0,Why Biomarin's Stock Is Trading Higher Today,2020-06-10 11:03:00-04:00,BMRN,neutral
174092.0,Biomarin Pharmaceutical shares are trading higher after Bank of America Securities maintained its Buy rating on the stock and raised the price target from $120 to $130 per share.,2020-06-10 08:46:00-04:00,BMRN,positive
174093.0,"B of A Securities Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to $130",2020-06-10 07:52:00-04:00,BMRN,positive
174094.0,"The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid",2020-06-05 07:34:00-04:00,BMRN,positive
174095.0,Stocks That Hit 52-Week Highs On Thursday,2020-06-04 10:48:00-04:00,BMRN,neutral
174096.0,"The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic",2020-06-04 08:13:00-04:00,BMRN,positive
174097.0,Biomarin Reports Longest Duration of Clinical Experience for a Gene Therapy in Hemophilia A,2020-05-31 16:03:00-04:00,BMRN,neutral
174098.0,"The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas",2020-05-27 07:25:00-04:00,BMRN,positive
174099.0,Shares of several healthcare companies are trading higher in sympathy with the overall market as equities rally on coronavirus vaccine hopes as well as a pickup in economic activity as some US states reopen businesses.,2020-05-26 11:58:00-04:00,BMRN,positive
174100.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-26 10:32:00-04:00,BMRN,neutral
174101.0,BioMarin Announces Plans to Offer $500M of Convertible Notes,2020-05-11 07:53:00-04:00,BMRN,neutral
174102.0,5 Biopharmas Where BofA Would Put Its Money To Work,2020-05-08 11:23:00-04:00,BMRN,neutral
174103.0,BioMarin Strikes Gene Therapy Partnership Targeting Rare Genetic Cardiomyopathies,2020-05-04 10:43:00-04:00,BMRN,negative
174104.0,BioMarin Announces Preclinical Collaboration and License Agreement with DiNAQOR to Develop Gene Therapies for Rare Genetic Cardiomyopathies,2020-05-04 05:32:00-04:00,BMRN,positive
174105.0,Shares of several healthcare companies are trading lower as markets dip following recent strength. Markets have sold off as investors weigh recent earnings and amid concerns of renewed US-China trade frictions.,2020-05-01 12:35:00-04:00,BMRN,positive
174106.0,"SunTrust Robinson Humphrey Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $109",2020-04-30 12:07:00-04:00,BMRN,negative
174107.0,"Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to $128",2020-04-30 09:16:00-04:00,BMRN,positive
174108.0,"Biomarin Pharmaceutical Q1 EPS $0.440 Beats $0.050 Estimate, Sales $502.100M Beat $468.770M Estimate",2020-04-29 16:06:00-04:00,BMRN,neutral
174109.0,"The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda",2020-04-29 08:40:00-04:00,BMRN,positive
174110.0,"The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update",2020-04-28 07:36:00-04:00,BMRN,neutral
174111.0,Stocks That Hit 52-Week Highs On Monday,2020-04-27 10:21:00-04:00,BMRN,neutral
174112.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,BMRN,negative
174113.0,"BioMarin Pharma Reports Regulatory Submissions For Marketing Authorization Of Vosoritide To Treat Children With Achondroplasia In Q3 In US, Europe",2020-04-06 08:34:00-04:00,BMRN,positive
174114.0,"Shares of several healthcare companies are trading higher amid market strength. NOTE: The coronavirus pandemic has potentially benefited the sector due to demand for medical supplies, testing and treatment candidates",2020-03-31 12:00:00-04:00,BMRN,positive
174115.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 10:58:00-04:00,BMRN,positive
174116.0,Shares of several healthcare companies are trading lower amid market volatility. Sunday's fiscal stimulus bill failed a procedural senate vote while the Fed Monday morning announced further stimulus measures to support liquidity.,2020-03-23 11:31:00-04:00,BMRN,negative
174117.0,"Shares of several healthcare companies are trading lower as the coronavirus outbreak continues to cause economic disruption around the globe, leading to a steep selloff in equities across sectors.",2020-03-16 10:50:00-04:00,BMRN,negative
174118.0,Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.,2020-03-13 09:29:00-04:00,BMRN,positive
174119.0,"The Daily Biotech Pulse: Breakthrough Device Designation For Neuronetics, AbbVie Receives European Label Expansion, AstraZeneca Flunks Late-Stage Study",2020-03-06 08:49:00-05:00,BMRN,negative
174120.0,"The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies",2020-03-04 07:37:00-05:00,BMRN,negative
174121.0,"Morgan Stanley Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $125",2020-03-03 08:12:00-05:00,BMRN,negative
174122.0,"Wedbush Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to $164",2020-03-02 10:00:00-05:00,BMRN,negative
174123.0,Biomarin Sees FY20 Sales $1.95B-$2.05B vs $1.53B Estimate,2020-02-26 16:21:00-05:00,BMRN,neutral
174124.0,"Biomarin Pharmaceutical Q4 EPS $0.08 Beats $(0.09) Estimate, Sales $454.4M Miss $459.33M Estimate",2020-02-26 16:20:00-05:00,BMRN,negative
174125.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,BMRN,negative
174126.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,BMRN,neutral
174127.0,Biomarin Pharmaceutical shares are trading higher after the FDA accepted for priority review the company's Biologics License Application for valoctocogene roxaparvovec.,2020-02-21 10:58:00-05:00,BMRN,positive
174128.0,"The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion",2020-02-21 07:46:00-05:00,BMRN,negative
174129.0,Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.,2020-02-05 09:47:00-05:00,BMRN,positive
174130.0,"The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares",2020-02-04 07:51:00-05:00,BMRN,negative
174131.0,BioMarin Announces CFO Succession; Brian R. Mueller To Assume CFO Role,2020-02-03 16:30:00-05:00,BMRN,positive
174132.0,﻿Shares of several healthcare companies are trading lower as fears of the coronavirus' potential impact on the global economy intensifies. The death toll continues to rise and the U.K. and Russia confirmed their first cases.,2020-01-31 11:41:00-05:00,BMRN,negative
174133.0,"Benzinga's Top Upgrades, Downgrades For January 28, 2020",2020-01-28 09:43:00-05:00,BMRN,positive
174134.0,"BMO Capital Initiates Coverage On Biomarin Pharmaceutical with Market Perform Rating, Announces $94 Price Target",2020-01-28 06:52:00-05:00,BMRN,neutral
174135.0,"Barron's Picks And Pans: BioMarin, Caesars, Royal Caribbean And More",2020-01-26 09:55:00-05:00,BMRN,neutral
174136.0,RBC Capital Upgrades Biomarin Pharmaceutical to Sector Outperform,2020-01-24 06:51:00-05:00,BMRN,neutral
174137.0,BioMarin To Begin Clinical Trial With BMN 307 Gene Therapy; Expects To Start Dosing Patients In Phase 1 Trial In Q1 Of 2020,2020-01-13 08:31:00-05:00,BMRN,neutral
174138.0,BioMarin to Begin Clinical Trial with BMN 307 Gene Therapy,2020-01-13 08:31:00-05:00,BMRN,neutral
174139.0,Biomarin Pharmaceutical shares are trading higher potentially in anticipation of JPMorgan's Healthcare Conference.,2020-01-10 14:28:00-05:00,BMRN,positive
174140.0,"A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations",2020-01-10 08:52:00-05:00,BMRN,neutral
174141.0,Biomarin Pharmaceuticals shares are trading higher. Not seeing any news to justify the price action.,2020-01-09 11:00:00-05:00,BMRN,positive
174142.0,"Benzinga's Top Upgrades, Downgrades For January 2, 2020",2020-01-02 10:42:00-05:00,BMRN,positive
174143.0,10 Biotech M&A Targets Under The Scanner For 2020,2019-12-24 07:30:00-05:00,BMRN,neutral
174144.0,A Perspective On Biopharma's Record M&A Run In 2019,2019-12-23 14:57:00-05:00,BMRN,neutral
174145.0,BioMarin Submits Biologics License Application To FDA For Valoctocogene Roxaparvovec To Treat Hemophilia A,2019-12-23 08:45:00-05:00,BMRN,positive
174146.0,European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec To Treat Severe Hemophilia A,2019-12-23 08:32:00-05:00,BMRN,positive
174147.0,Biomarin Pharmaceuticals shares are trading higher after the company announced positive results for its Phase 3 study of Vosoritide.,2019-12-16 08:47:00-05:00,BMRN,positive
174148.0,BioMarin Announces Positive Results From its Phase 3 Study of Vosoritide,2019-12-16 08:18:00-05:00,BMRN,positive
174149.0,Invitae Announces Program With BioMarin To Expand Access To Genetic Testing For Skeletal Dysplasias,2019-12-10 07:38:00-05:00,BMRN,positive
174150.0,The Gene Therapy Names Moving On The Audentes Buyout Deal,2019-12-03 11:53:00-05:00,BMRN,neutral
174151.0,Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.,2019-12-02 11:31:00-05:00,BMRN,negative
174152.0,Biomarin Pharmaceutical shares are trading higher after Barclays upgraded the company's stock from Equal-Weight to Overweight and announced a $98 price target.,2019-11-27 10:58:00-05:00,BMRN,negative
174153.0,"Benzinga's Top Upgrades, Downgrades For November 27, 2019",2019-11-27 09:47:00-05:00,BMRN,positive
174154.0,"Barclays Upgrades Biomarin Pharmaceutical to Overweight, Announces $98 Price Target",2019-11-27 07:33:00-05:00,BMRN,negative
174155.0,BioMarin Reports Submission Of Marketing Authorization Application To EMA For Valoctocogene Roxaparvovec To Treat Severe Hemophilia A,2019-11-21 16:04:00-05:00,BMRN,neutral
174156.0,Biomarin Pharmaceutical shares are trading higher. Not seeing any news to justify the price action.,2019-11-19 15:45:00-05:00,BMRN,positive
174157.0,BioMarin Sees Vosoritide Phase 3 Topline Results By End Of 2019,2019-11-14 11:03:00-05:00,BMRN,neutral
174158.0,"BioMarin Says Valoctocogene Roxaparvovec On Track For US, EU Regulatory Submission By End Of 2019",2019-11-14 11:03:00-05:00,BMRN,neutral
174159.0,BioMarin Sees FY20 GAAP EPS Breakeven Or Better,2019-11-14 11:02:00-05:00,BMRN,positive
174160.0,BioMarin Offers Update On Clinical Program For Vosoritide In Children With Achondroplasia,2019-11-14 08:35:00-05:00,BMRN,neutral
174161.0,"Benzinga's Top Upgrades, Downgrades For November 12, 2019",2019-11-12 09:37:00-05:00,BMRN,positive
174162.0,"SunTrust Robinson Humphrey Initiates Coverage On Biomarin Pharmaceutical with Buy Rating, Announces $110 Price Target",2019-11-12 06:14:00-05:00,BMRN,neutral
174163.0,Biomarin Pharmaceutical Option Alert: Nov 15 $75 Calls Sweep (5) near the Ask: 1338 @ $1.801 vs 3126 OI; Ref=$74.87,2019-11-06 13:47:00-05:00,BMRN,positive
174164.0,"Citigroup Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $95",2019-10-30 07:34:00-04:00,BMRN,negative
174165.0,"Canaccord Genuity Maintains Buy on Biomarin Pharmaceutical, Lowers Price Target to $108",2019-10-28 08:49:00-04:00,BMRN,negative
174166.0,"Wedbush Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $152",2019-10-25 09:11:00-04:00,BMRN,neutral
174167.0,"Barclays Maintains Equal-Weight on Biomarin Pharmaceutical, Lowers Price Target to $86",2019-10-24 09:03:00-04:00,BMRN,negative
174168.0,"Nomura Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to $77",2019-10-24 08:11:00-04:00,BMRN,negative
174169.0,"Biomarin Pharmaceutical Q3 EPS $0.30 Beats $0.07 Estimate, Sales $461.1M Beat $454.22M Estimate",2019-10-23 16:11:00-04:00,BMRN,neutral
174170.0,Biomarin Pharmaceuticals shares are trading higher on anticipation of the release of the company's Q3 earnings scheduled for release today after the close.,2019-10-23 11:53:00-04:00,BMRN,positive
174171.0,"The Daily Biotech Pulse: Eli Lily Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data",2019-10-23 07:54:00-04:00,BMRN,negative
174172.0,"The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict",2019-10-20 08:08:00-04:00,BMRN,positive
174173.0,"Bank of America Reinstates Buy on Biomarin Pharmaceutical, Announces $90 Price Target",2019-10-17 07:28:00-04:00,BMRN,neutral
174174.0,"The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo",2019-10-03 07:34:00-04:00,BMRN,negative
174175.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-02 10:55:00-04:00,BMRN,negative
174176.0,"The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data",2019-10-02 07:17:00-04:00,BMRN,positive
174177.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-01 14:35:00-04:00,BMRN,negative
174178.0,"Shares of several healthcare stocks are trading lower in sympathy with the overall market after the Institute for Supply Management said U.S. manufacturing activity shrunk to its lowest level since June 2009, adding fears of an economic slowdown.",2019-10-01 13:02:00-04:00,BMRN,negative
174179.0,"The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines",2019-10-01 08:10:00-04:00,BMRN,negative
174180.0,Stocks That Hit 52-Week Lows On Monday,2019-09-30 11:20:00-04:00,BMRN,negative
174181.0,Biomarin Pharmaceuticals shares are trading lower. Not seeing any news to justify the price action.,2019-09-27 15:32:00-04:00,BMRN,neutral
174182.0,"The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave",2019-09-27 07:56:00-04:00,BMRN,positive
174183.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,BMRN,neutral
174184.0,BioMarin Submits Clinical Trial Application In UK For Investigational Gene Therapy For PKU,2019-09-26 08:39:00-04:00,BMRN,neutral
174185.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,BMRN,negative
174186.0,Biomarin Pharmaceutical shares are trading higher after the company announced it would participated at the Morgan Stanley 17th Annual Global Healthcare Conference.,2019-09-10 14:36:00-04:00,BMRN,positive
174187.0,Biomarin Pharmaceutical Option Alert: Sep 20 $85 Calls Sweep (5) near the Ask: 832 @ $0.858 vs 1886 OI; Ref=$77.95,2019-08-22 13:49:00-04:00,BMRN,positive
174188.0,Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.,2019-08-19 12:31:00-04:00,BMRN,positive
174189.0,Biomarin Pharmaceutical Option Alert: Sep 20 $85 Calls Sweep (39) near the Ask: 501 @ $0.65 vs 492 OI; Ref=$75.65,2019-08-16 14:05:00-04:00,BMRN,positive
174190.0,"Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.",2019-08-16 13:27:00-04:00,BMRN,negative
174191.0,Stocks That Hit 52-Week Lows On Thursday,2019-08-15 11:29:00-04:00,BMRN,negative
174192.0,"The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings",2019-08-15 07:45:00-04:00,BMRN,neutral
174193.0,Stocks That Hit 52-Week Lows On Wednesday,2019-08-14 12:46:00-04:00,BMRN,negative
174194.0,Stocks That Hit 52-Week Lows On Tuesday,2019-08-13 11:08:00-04:00,BMRN,negative
174195.0,"The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results",2019-08-13 07:25:00-04:00,BMRN,neutral
174196.0,Shares of several healthcare companies are trading lower in sympathy with the overall market as the Treasury yield continues to decline along with ongoing trade tensions with China.,2019-08-12 15:33:00-04:00,BMRN,positive
174197.0,Stocks That Set New 52-Week Lows Friday Morning,2019-08-02 10:46:00-04:00,BMRN,negative
174198.0,40 Healthcare Stocks Moving In Thursday's After-Market Session,2019-08-02 04:10:00-04:00,BMRN,neutral
174199.0,"Biomarin Pharmaceutical Q2 EPS $(0.21) May Not Compare To $(0.1) Estimate, Sales $387.8M Miss $414.4M Estimate",2019-08-01 16:48:00-04:00,BMRN,negative
174200.0,"The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings",2019-08-01 07:18:00-04:00,BMRN,negative
174201.0,New 52-Week Lows for Tuesday Morning,2019-07-30 11:07:00-04:00,BMRN,negative
174202.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,BMRN,negative
174203.0,Biomarin Pharmaceutical Option Alert: Aug 16 $95 Calls at the Ask: 1981 @ $0.5 vs 297 OI; Earnings 8/1 After Close Ref=$82.2101,2019-07-19 13:28:00-04:00,BMRN,positive
174204.0,Biomarin Pharmaceutical Option Alert: Aug 16 $90 Calls Sweep (34) near the Ask: 514 @ $0.851 vs 529 OI; Earnings 8/1 After Close Ref=$82.15,2019-07-19 13:27:00-04:00,BMRN,positive
174205.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,BMRN,negative
174206.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,BMRN,positive
174207.0,BioMarin Plans Regulatory Submissions For Marketing Authorization Of Valoctocogene Roxaparvovec To Treat Severe Hemophilia A In 4Q 2019 In US And Europe,2019-07-08 08:06:00-04:00,BMRN,negative
174208.0,BioMarin Receives $15M In Milestone Payments From Pfizer For TALZENNA For Metastatic Breast Cancer Patients With An Inherited BRCA Mutation,2019-06-21 11:32:00-04:00,BMRN,negative
174209.0,BioMarin Announces New England Journal Of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up To 42 Months In Children With Achondroplasia,2019-06-18 08:32:00-04:00,BMRN,positive
174210.0,Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.,2019-06-17 10:10:00-04:00,BMRN,positive
174211.0,BioMarin Receives Approval Of Vimizim In China For Treatment Of Morquio A Syndrome,2019-06-04 08:30:00-04:00,BMRN,positive
174212.0,"A Look At Benzinga Pro's Most-Searched Tickers For May 29, 2019",2019-05-29 12:12:00-04:00,BMRN,neutral
174213.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wed., May 29, 2019",2019-05-29 10:06:00-04:00,BMRN,positive
174214.0,"Benzinga Pro's Top Most Searched Tickers For May 28, 2019",2019-05-28 11:28:00-04:00,BMRN,positive
174215.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tue., May 28, 2019",2019-05-28 10:13:00-04:00,BMRN,positive
174216.0,30 Stocks Moving In Tuesday's Pre-Market Session,2019-05-28 08:17:00-04:00,BMRN,neutral
174217.0,"BioMarin Announces  Phase 3 Cohort Of Valoctocogene Roxaparvovec, Gene Therapy Study In Severe Hemophilia A Met Pre-Specified Criteria For Regulatory Submissions In US and Europe",2019-05-28 06:58:00-04:00,BMRN,negative
174218.0,BioMarin 3-Year Clinical Data From Ongoing Phase 1/2 Study Of Valoctocogene Roxaparvovec Gene Therapy For Severe Hemophilia A Shows 'Substantial Reduction In Excess Of 92% In Mean Bleed Rate Requiring Factor VIII Infusions',2019-05-28 06:51:00-04:00,BMRN,negative
174219.0,BioMarin shares trading higher on no fundamental news. The stock rebounded from just below the $80 level on Friday and tested that support level again on Monday.,2019-05-15 14:03:00-04:00,BMRN,positive
174220.0,5 Biotech Stocks With Near-Term Catalysts Ahead,2019-05-02 14:18:00-04:00,BMRN,neutral
174221.0,Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.,2019-04-30 12:16:00-04:00,BMRN,negative
174222.0,"Wedbush Maintains Outperform on BioMarin Pharmaceutical Inc. - Common Stock, Raises Price Target to $128",2019-04-26 10:53:00-04:00,BMRN,neutral
174223.0,"The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug",2019-04-26 08:02:00-04:00,BMRN,negative
174224.0,"BioMarin Sees FY19 Sales $1.68B-$1.75B vs $1.69B Estimate, Adj. Net Income $130M-$170M",2019-04-25 16:20:00-04:00,BMRN,neutral
174225.0,"Biomarin Pharmaceutical Q1 GAAP EPS $(0.32) May Not Compare To $(0.19) Estimate, Sales $400.7M Beat $391.54M Estimate",2019-04-25 16:19:00-04:00,BMRN,neutral
174226.0,"The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings",2019-04-25 07:58:00-04:00,BMRN,neutral
174227.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs",2019-04-21 14:06:00-04:00,BMRN,neutral
174228.0,Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.,2019-04-17 10:38:00-04:00,BMRN,positive
174229.0,Get In On Genomics With This New ETF,2019-04-10 08:01:00-04:00,BMRN,neutral
174230.0,"Raymond James Reinstates Outperform on Biomarin Pharmaceutical, Announces $110 Price Target",2019-04-09 07:51:00-04:00,BMRN,neutral
174231.0,6 Gene Therapy M&A Targets On The Radar,2019-03-27 12:45:00-04:00,BMRN,neutral
174232.0,BioMarin Reports Received Positive CHMP Opinion For Palynziq For Treatment Of Patients With Phenylketonuria Aged 16 and Older,2019-03-01 07:31:00-05:00,BMRN,positive
174233.0,Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal,2019-02-25 15:12:00-05:00,BMRN,positive
174234.0,Biomarin Pharma shares are trading higher in sympathy to Spark Therapeutics which was acquired by Roche earlier Monday.,2019-02-25 08:26:00-05:00,BMRN,positive
174235.0,BioMarin Pharma shares are trading lower after the company reported Q4 sales of $353 million versus the $380 million analyst estimate.,2019-02-22 09:05:00-05:00,BMRN,neutral
174236.0,"The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data",2019-02-22 08:50:00-05:00,BMRN,neutral
174237.0,"Biomarin Pharmaceutical Q4 GAAP EPS $(0.03), Adj. Net Loss $10.8M, Sales $353.214M Miss $379.79M Estimate",2019-02-21 16:16:00-05:00,BMRN,negative
174238.0,"The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan",2019-02-21 07:32:00-05:00,BMRN,positive
174239.0,"The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs",2019-02-08 09:17:00-05:00,BMRN,negative
174240.0,Biomarin Announces Ongoing Study Demonstrates Durable Treatment Benefit From Brineura For 3 Years; Reduced Rate Of Decline Maintained In Children With CLN2 Disease,2019-02-07 16:30:00-05:00,BMRN,positive
174241.0,Biomarin Pharmaceuticals shares are trading down after the company cut FY18 adj. net income guidance.,2019-01-09 14:50:00-05:00,BMRN,neutral
174242.0,"The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study",2019-01-09 07:39:00-05:00,BMRN,negative
174243.0,BioMarin Cuts FY18 Adj. Net Income Guidance From $100M-$140M To $90M-$105M,2019-01-08 16:26:00-05:00,BMRN,negative
174244.0,UPDATE: BioMarin Reaffirms FY18 Total Sales Guidance $1.47B-$1.53B vs $1.52B Estimate,2019-01-08 16:25:00-05:00,BMRN,neutral
174245.0,BioMarin 8-K Shows Slides For JP Morgan Healthcare Conference Presentation,2019-01-08 16:25:00-05:00,BMRN,positive
174246.0,"Benzinga's Top Upgrades, Downgrades For January 2, 2019",2019-01-02 09:15:00-05:00,BMRN,positive
174247.0,Raymond James Downgrades Biomarin Pharmaceutical to Market Perform,2019-01-02 07:35:00-05:00,BMRN,neutral
174248.0,Shares of Biomarin Pharmaceuticals are trading lower after Guggenheim initiated coverage on the stock with a Neutral rating.,2018-12-18 15:08:00-05:00,BMRN,neutral
174249.0,Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved,2018-12-18 08:55:00-05:00,BMRN,positive
174250.0,Guggenheim Initiates Coverage On Biomarin Pharmaceutical with Neutral Rating,2018-12-18 07:16:00-05:00,BMRN,neutral
174251.0,Oppenheimer Initiates Coverage On Biomarin Pharmaceutical with Perform Rating,2018-12-14 09:56:00-05:00,BMRN,neutral
174252.0,5 Biotech Companies To Keep On Your M&A Watchlist For 2019,2018-12-10 12:32:00-05:00,BMRN,neutral
174253.0,BioMarin Says PKU Gene Therapy Planned For 2H 2019,2018-11-07 10:18:00-05:00,BMRN,neutral
174254.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,BMRN,neutral
174255.0,"The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default",2018-10-26 08:17:00-04:00,BMRN,negative
174256.0,"Biomarin Pharmaceutical Q3 GAAP EPS $(0.07) Beats $(0.22) Estimate, Sales $391.706M Beat $367.09M Estimate",2018-10-25 16:19:00-04:00,BMRN,neutral
174257.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,BMRN,negative
174258.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs",2018-10-21 17:15:00-04:00,BMRN,neutral
174259.0,BioMarin Receives $15M Milestone Payments From Pfizer For TalzennaFor Metastatic Breast Cancer Patients; Milestones Triggered By FDA Approval Of Talzenna,2018-10-16 12:59:00-04:00,BMRN,negative
174260.0,3 Screens That Hint At Which Stocks May Outperform In Q4,2018-10-05 11:57:00-04:00,BMRN,neutral
174261.0,"Benzinga's Top Upgrades, Downgrades For October 1, 2018",2018-10-01 09:05:00-04:00,BMRN,positive
174262.0,"Cantor Fitzgerald Initiates Coverage On Biomarin Pharmaceutical with Overweight Rating, Announces $126 Price Target",2018-10-01 08:16:00-04:00,BMRN,negative
174263.0,"Express Scripts in Talks With Biomarin Pharmaceutical, Spark Therapeutics, Bluebird Bio to have Specialty Pharmaceutical Business Exclusively Distribute Their New Hemophilia Treatments",2018-08-15 04:20:00-04:00,BMRN,positive
174264.0,"Citigroup Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to $120",2018-08-09 08:35:00-04:00,BMRN,neutral
174265.0,"Stocks Which Set New 52-Week High Yesterday, August 7th",2018-08-08 11:01:00-04:00,BMRN,neutral
174266.0,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",2018-08-08 08:15:00-04:00,BMRN,positive
174267.0,"Barclays Maintains Equal-Weight on Biomarin Pharmaceutical, Raises Price Target to $98",2018-08-06 08:15:00-04:00,BMRN,neutral
174268.0,"Wedbush Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $120",2018-08-06 08:04:00-04:00,BMRN,neutral
174269.0,"Stifel Nicolaus Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to $109",2018-08-03 07:42:00-04:00,BMRN,neutral
174270.0,"Morgan Stanley Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $115",2018-08-03 07:14:00-04:00,BMRN,negative
174271.0,"Biomarin Pharmaceutical Q2 EPS $(0.09) Beats $(0.20) Estimate, Sales $372.845M Beat $357.5M Estimate",2018-08-02 16:30:00-04:00,BMRN,neutral
174272.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,BMRN,positive
174273.0,"Canaccord Genuity Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to $113",2018-07-31 08:04:00-04:00,BMRN,neutral
174274.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,BMRN,neutral
174275.0,"Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $122",2018-07-09 09:22:00-04:00,BMRN,positive
174276.0,BioMarin Doses Initial Participant in Phase 2 Study of Vosoritide,2018-06-14 08:31:00-04:00,BMRN,neutral
174277.0,BioMarin Receives $20M Milestone Payments From Pfizer For Talazoparib,2018-06-07 08:16:00-04:00,BMRN,neutral
174278.0,"JP Morgan Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $133",2018-05-31 07:57:00-04:00,BMRN,neutral
174279.0,7 Biggest Price Target Changes For Tuesday,2018-05-29 10:37:00-04:00,BMRN,neutral
174280.0,"Wedbush Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $115",2018-05-29 08:34:00-04:00,BMRN,neutral
174281.0,"Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $120",2018-05-25 11:35:00-04:00,BMRN,positive
174282.0,7 Biggest Price Target Changes For Friday,2018-05-25 10:20:00-04:00,BMRN,neutral
174283.0,"Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended",2018-05-25 09:19:00-04:00,BMRN,negative
174284.0,"Canaccord Genuity Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to $105",2018-05-25 08:14:00-04:00,BMRN,neutral
174285.0,BioMarin Receives Standard FDA Approval for Palynziq,2018-05-24 17:42:00-04:00,BMRN,positive
174286.0,UPDATE: FDA Is Planning Easier Approval For Experimental Gene Therapies,2018-05-22 12:47:00-04:00,BMRN,positive
174287.0,Watching Gene Therapy Stocks Amid Report FDA Could Allow Gene Therapy Approval On Surrogate Endpoints,2018-05-22 12:46:00-04:00,BMRN,positive
174288.0,"Hearing Citi Out Defending BioMarin's Valoctocogene Roxaparvovec Data Released This Morning, Unconfirmed",2018-05-22 09:52:00-04:00,BMRN,negative
174289.0,"Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict",2018-05-22 08:05:00-04:00,BMRN,positive
174290.0,BioMarin Provides 2 Years Of Clinical Data In 6e13 vg/kg Dose From Ongoing Phase 1/2 Study In Valoctocogene Roxaparvovec Gene Therapy For Severe Hemophilia A At World Federation Of Hemophilia 2018 World Congress,2018-05-22 07:36:00-04:00,BMRN,negative
174291.0,"The Week Ahead: Target, Best Buy Help Close Out Earnings Season",2018-05-21 14:08:00-04:00,BMRN,positive
174292.0,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",2018-05-21 07:40:00-04:00,BMRN,neutral
174293.0,"Benzinga's Top Upgrades, Downgrades For May 16, 2018",2018-05-16 09:15:00-04:00,BMRN,positive
174294.0,"Canaccord Genuity Initiates Coverage On Biomarin Pharmaceutical with Buy Rating, Announces $101 Price Target",2018-05-16 06:25:00-04:00,BMRN,neutral
174295.0,BioMarin Reports First Patient Dosed In Phase 1/2 Study Evaluating Valoctocogene Roxaparvovec Gene Therapy In severe Hemophilia A Patients With Pre-Existing AAV5 Antibodies,2018-05-15 08:36:00-04:00,BMRN,negative
174296.0,BioMarin Shares Unaffected As Traders Circulate Word CEO Will Be On CNBC's 'Mad Money' Thurs. Evening,2018-05-10 11:11:00-04:00,BMRN,negative
174297.0,Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates,2018-05-01 15:39:00-04:00,BMRN,neutral
174298.0,"Morgan Stanley Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $113.00",2018-04-30 09:17:00-04:00,BMRN,negative
174299.0,"Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings",2018-04-26 08:07:00-04:00,BMRN,neutral
174300.0,"BioMarin Sees FY18 Adj. Net Income $100M-$140M, Sales $1.47B-$1.53B vs $1.49B Est.",2018-04-25 16:08:00-04:00,BMRN,neutral
174301.0,"BioMarin Pharma Q1 EPS $(0.26) Misses $(0.18) Est., Sales $373.4M Beats $348.57M Est.",2018-04-25 16:08:00-04:00,BMRN,negative
174302.0,"Benzinga's Biotech Pulse: Takeda Sweetens Shire Offer Again, Menlo's Woes Abound, Earnings Fail to Boost Amgen",2018-04-25 07:46:00-04:00,BMRN,negative
174303.0,"BioMarin Highlights Updated Results From Study Evaluating Efficacy, Safety Of Brineura In Children With CLN2 Disease Published In NEJM; Showed '...patients treated with Brineura experienced a slower rate of decline in motor and language function...'",2018-04-24 14:34:00-04:00,BMRN,positive
174304.0,Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure,2018-04-24 10:49:00-04:00,BMRN,positive
174305.0,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",2018-04-20 14:00:00-04:00,BMRN,neutral
174306.0,BioMarin Shares Down 3.2% From Session High,2018-04-20 13:52:00-04:00,BMRN,positive
174307.0,BioMarin Reports EMA Accepted Co.'s Marketing Application For Pegvaliase MAA For Treatment Of PKU,2018-03-28 16:14:00-04:00,BMRN,positive
174308.0,"Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $116.00",2018-03-02 07:53:00-05:00,BMRN,positive
174309.0,Why Leerink Adjusted Upside Expectations For 3 Biotechs,2018-02-23 11:52:00-05:00,BMRN,neutral
174310.0,"Morgan Stanley Maintains Overweight on Biomarin Pharmaceutical, Lowers price target to $112.00",2018-02-23 10:39:00-05:00,BMRN,negative
174311.0,"Stifel Nicolaus Maintains Buy on Biomarin Pharmaceutical, Lowers price target to $102.00",2018-02-23 10:19:00-05:00,BMRN,negative
174312.0,"Leerink Swann Maintains Outperform on Biomarin Pharmaceutical, Lowers price target to $132.00",2018-02-23 09:50:00-05:00,BMRN,negative
174313.0,"BMO Capital Maintains Outperform on Biomarin Pharmaceutical, Raises price target to $125.00",2018-02-23 09:32:00-05:00,BMRN,neutral
174314.0,"Deutsche Bank Maintains Buy on Biomarin Pharmaceutical, Raises price target to $124.00",2018-02-23 09:11:00-05:00,BMRN,neutral
174315.0,BioMarin Sees FY18 Sales $1.47-$1.53B vs $1.48B Est.,2018-02-22 16:15:00-05:00,BMRN,neutral
174316.0,"BioMarin Reports Q4 EPS $(0.30) vs $(0.23) Est., Sales $358.3M vs $351M Est.",2018-02-22 16:14:00-05:00,BMRN,neutral
174317.0,Biomarin Pharmaceutical Q4 Earnings Outlook,2018-02-22 10:10:00-05:00,BMRN,neutral
174318.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-02-19 10:50:00-05:00,BMRN,neutral
174319.0,BioMarin Reports Interim Phase 1/2 Data Of BMN 250 For Treatment Of MPS IIIB: 'Normalization of biomarker and liver size; stabilization of early cognitive effects suggested in preliminary data',2018-02-07 12:16:00-05:00,BMRN,neutral
174320.0,"CNBC's Meg Tirrell Tweets 'Spoke w $PFE mgmt team after the call...about gene therapy safety concerns...pointed out none with $PFE $AVXS $ONCE $BMRN studies. Said...surprised Wilson & $SLDB ""didn't have any way to resolve"" concerns [properly]'",2018-01-30 12:48:00-05:00,BMRN,positive
174321.0,"Cara Therapeutics Shares Up 19.24% As Co. Mentioned In Earlier Opinion Piece As Potential M&A Target; Other Mentions Include: BMRN -0.66%, BLUE +3.87%, ACAD -0.3%, INCY +0.4%",2018-01-24 13:40:00-05:00,BMRN,positive
174322.0,How To Trade The JPMorgan Healthcare Conference,2018-01-08 13:19:00-05:00,BMRN,neutral
174323.0,Wall Street Reacts To Spark Therapeutics' $850K Genetic Blindness Treatment,2018-01-03 11:59:00-05:00,BMRN,positive
174324.0,BioMarin Announces a PDUFA Extension for Pegvaliase Biologics License Application Until May 28,2017-12-22 08:32:00-05:00,BMRN,neutral
174325.0,BioMarin Doses First Patient In GENEr8-1 Phase 3 Study Of Valoctocogene Roxaparvovec,2017-12-19 16:06:00-05:00,BMRN,neutral
174326.0,"UPDATE: Goldman Added Alnylam and Biomarin To 2018 Conviction Buy List Earlier This Morning, Hologic Was Added To Conviction Buy List On 12/7 For 2018",2017-12-15 08:56:00-05:00,BMRN,neutral
174327.0,"Goldman Adds Biomarin, Alnylam To Conviction Buy List For 2018; Earlier Post Said That Hologic Was Added To Conviction Buy List For 2018, That Note Was Updated Today, But Was Originally Published 12/7",2017-12-15 08:25:00-05:00,BMRN,neutral
174328.0,"Wedbush Finally Steps Off The Sidelines, Bumps BioMarin To Outperform",2017-12-14 15:26:00-05:00,BMRN,neutral
174329.0,"Benzinga's Top Upgrades, Downgrades For December 14, 2017",2017-12-14 08:58:00-05:00,BMRN,positive
174330.0,Wedbush Upgrades Biomarin Pharmaceutical to Outperform,2017-12-14 06:50:00-05:00,BMRN,neutral
174331.0,"ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More",2017-12-13 12:31:00-05:00,BMRN,neutral
174332.0,11 Biotech Stocks Moving From ASH 2017,2017-12-11 16:24:00-05:00,BMRN,neutral
174333.0,Biomarin Option Alert: Fri $80 Calls Sweep (38) at the Ask: 859 @ $8.0 vs 201 OI; Ref=$87.65,2017-12-11 13:06:00-05:00,BMRN,positive
174334.0,"BioMarin Shares Up 6.38% After Reporting Saturday From ASH Data For Valoctocogene Roxaparvovec, Co. Expects To Begin Enrolling Patients In Phase 3 GENEr8 Studies This Month",2017-12-11 12:45:00-05:00,BMRN,positive
174335.0,BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at #ASH2017,2017-12-09 07:51:00-05:00,BMRN,negative
174336.0,BioMarin Sells Second Priority Review Voucher from the FDA for $125 Million,2017-11-27 08:45:00-05:00,BMRN,neutral
174337.0,9 Notable Biotechs Presenting At This Year's ASH Meeting,2017-11-06 16:31:00-05:00,BMRN,neutral
174338.0,BioMarin Narrows FY17 Sales Outlook From $1.285B-$1.335B To $1.29B-$1.32B vs $1.31B Est.,2017-10-26 16:15:00-04:00,BMRN,neutral
174339.0,"BioMarin Reports Q3 GAAP EPS $(0.07) May Not Compare To $(0.12) Est., Sales $334.1M vs $349.6M Est.",2017-10-26 16:14:00-04:00,BMRN,neutral
174340.0,BioMarin Reports FDA Granted Breakthrough Therapy Designation For Co.'s Valoctocogene Roxaparvovec,2017-10-26 08:31:00-04:00,BMRN,positive
174341.0,Biomarin Shares Down 6.6% As Co. Says At Investor Day That Slowing Of Govt. Purchases In Brazil May Impact Revenue Guidance,2017-10-18 13:17:00-04:00,BMRN,positive
174342.0,"BioMarin Names Robert J. Hombach, Former Baxalta CFO and COO, To Board Of Directors",2017-10-03 08:31:00-04:00,BMRN,neutral
174343.0,RBC Initiated Coverage On 33 Pharma/Biotech Cos.,2017-09-15 07:38:00-04:00,BMRN,neutral
174344.0,"UPDATE: Biomarin Says FDA Has Requested Additional CMC Information For Pegvaliase, Which Co. Expects Will Extend 2/28/18 PDUFA Date By 3 Months",2017-09-14 16:13:00-04:00,BMRN,positive
174345.0,BioMarin Reports FDA Is Not Currently Planning Advisory Panel Meeting For Co.'s Pegvaliase BLA Regulatory Review Process,2017-09-14 16:07:00-04:00,BMRN,neutral
174346.0,PiperJaffray Assumes Biomarin Pharmaceutical to Overweight,2017-09-14 07:48:00-04:00,BMRN,negative
174347.0,"BioMarin Offers Interim Data Of Phase 1/2 Study Of BMN 250 For Treatment Of BPS IIIB: 'Preliminary biomarker and liver size data show marked decreases; early cognitive effects encouraging, pending more mature data'",2017-09-06 11:03:00-04:00,BMRN,positive
174348.0,Biomarin FDA Accepts BioMarin's Pegvaliase Biologics License Application and Grants Priority Review Designation,2017-08-29 16:07:00-04:00,BMRN,positive
174349.0,"Benzinga's Top Upgrades, Downgrades For August 17, 2017",2017-08-17 09:34:00-04:00,BMRN,positive
174350.0,Evercore ISI Group Initiates Coverage On Biomarin Pharmaceutical with Outperform Rating,2017-08-17 07:08:00-04:00,BMRN,neutral
174351.0,"BioMarin Reports Q2 GAAP EPS $(0.21) May Not Compare To $(0.21) Est., Sales $317.4M vs $309M Est.",2017-08-02 16:49:00-04:00,BMRN,neutral
174352.0,"BioMarin Reports Plans To Progress Both 6e13vg/kg, 4e13 vg/kg Doses Of BMN 270",2017-08-02 16:02:00-04:00,BMRN,positive
174353.0,"Bernstein Initiates Coverage On Biomarin Pharmaceutical with Market Perform Rating, Announces $89.00 Price Target",2017-07-27 07:55:00-04:00,BMRN,neutral
174354.0,"Wall Street's M&A Chatter From July 26: Biomarin, Sigma Designs, Colgate-Palmolive, Markel-State National",2017-07-27 07:24:00-04:00,BMRN,neutral
174355.0,BioMarin Shares Spike ~$0.50 Over Last Min. As Traders Circulate Chatter In Name,2017-07-26 11:18:00-04:00,BMRN,positive
174356.0,"Following Q2 Beat, Sarepta Has A Key Catalyst Coming In Q4",2017-07-20 11:20:00-04:00,BMRN,neutral
174357.0,"UPDATE: Sarepta Will Make 1-Time Payment Of $35M To BioMarin, Certain Added Regulatory, Commercial Milestone Payments For Exons 51, 45, 53, Possibly On Future Exon-Skipping Products",2017-07-18 08:33:00-04:00,BMRN,positive
174358.0,"Sarepta, BioMarin Report Execution Of Global Settlement, License Deal Resolving Exon Skipping Patent Litigation",2017-07-18 08:33:00-04:00,BMRN,positive
174359.0,"Analyst: Shire Shares Should Rebound, But Sustained Rally Unlikely",2017-07-12 09:15:00-04:00,BMRN,positive
174360.0,BioMarin's Investigational Gene Therapy for Hemophilia A at 6e13 vg/kg Dose Maintains Average Factor VIII Levels within Normal Range for over One Year,2017-07-11 04:12:00-04:00,BMRN,neutral
174361.0,A Barrage Of Biotech Updates Expected At ISTH Meeting,2017-07-07 17:08:00-04:00,BMRN,neutral
174362.0,BioMarin Submits Pegvaliase Biologics License Application To FDA,2017-06-30 09:11:00-04:00,BMRN,neutral
174365.0,"Companies Holding Shareholder Meetings Today Include: Acacia Research, BioMarin Pharmaceutical, AMC Networks, Live Nation Entertainment, Kate Spade, IMAX, GoPro, Netflix, Sarepta, Salesforce, TJX Companies, And Tesla",2017-06-06 09:00:00-04:00,BMRN,positive
174366.0,BioMarin Reports EC Approved Brineura for Treatment of CLN2 Disease,2017-06-01 08:33:00-04:00,BMRN,positive
174367.0,BioMarin Sees FY17 Sales $1.25-$1.3B vs $1.27B Est.,2017-05-04 16:03:00-04:00,BMRN,neutral
174368.0,"BioMarin  Reports Q1 EPS $(0.09) vs $(0.29) Est., Sales $303.74M vs $288M Est.",2017-05-04 16:02:00-04:00,BMRN,neutral
174369.0,BioMarin Issues Release Confirming FDA Approval of Brineura for Treatment of CLN2 Disease,2017-04-27 13:29:00-04:00,BMRN,positive
174370.0,Biomarin's Brineura (cerliponase alfa) Approved By FDA For Treatment For A Specific Form Of Batten Disease,2017-04-27 13:07:00-04:00,BMRN,positive
174371.0,Biomarin Cerliponase Alfa PDUFA Date Today,2017-04-27 07:59:00-04:00,BMRN,neutral
174372.0,Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates,2017-04-25 13:44:00-04:00,BMRN,positive
174373.0,Adam Feuerstein Tweets: $BMRN Rare Disease Drug Picks Up European Endorsement Ahead of FDA Action thestreet.com/story/14098902… via @TheStreet,2017-04-24 08:53:00-04:00,BMRN,positive
174374.0,EMA Recommends Approval Of Biomarin's Neuronal Ceroid Lipofuscinosis Drug,2017-04-21 13:28:00-04:00,BMRN,positive
174375.0,"BioMarin Reports Kuvan Patent Challenge Settlement: BioMarin Will Grant Par Non-Exclusive License to Patents, Allowing Par to Market Generic Version",2017-04-13 08:31:00-04:00,BMRN,positive
174376.0,Your Cheat Sheet For Q1 Biotech Earnings,2017-04-06 12:47:00-04:00,BMRN,negative
174377.0,Feuerstein Throws BioMarin Into Gilead Takeover Speculation,2017-04-05 11:28:00-04:00,BMRN,neutral
174378.0,"Feuerstein on Possibilities of Gilead Takeover Interest: Notes A Lot of Sources Have Talked About TESARO as Target, But Feels BioMarin is a Co. Which Has Better Chance to Move the Needle at Gilead",2017-04-05 09:03:00-04:00,BMRN,positive
174379.0,Feuerstein on Possibilities of Gilead Takeover Interest: Likes BioMarin as a Target,2017-04-05 09:01:00-04:00,BMRN,positive
174380.0,"Benzinga's Top Upgrades, Downgrades For March 30, 2017",2017-03-30 09:42:00-04:00,BMRN,positive
174381.0,"UBS Initiates Coverage On Biomarin Pharmaceutical With Neutral, Announces $92 Price Target",2017-03-30 07:10:00-04:00,BMRN,neutral
174382.0,Nomura Initiates Coverage On Biomarin Pharmaceutical at Neutral,2017-03-02 07:33:00-05:00,BMRN,neutral
174383.0,Expect A Pair Of Drug Approvals From BioMarin In 2017; Stock Remains Pricey,2017-02-27 08:17:00-05:00,BMRN,neutral
174384.0,BioMarin Sees FY17 Sales $1.25-$1.3B vs. $1.31B Est.,2017-02-23 16:02:00-05:00,BMRN,neutral
174385.0,"BioMarin Reports Q4 GAAP EPS $(0.53) vs. $(0.38) Est., Sales $300M vs. $295M",2017-02-23 16:02:00-05:00,BMRN,neutral
174386.0,Your Guide To 2017's Emerging Pharmaceuticals Catalysts,2017-02-07 14:39:00-05:00,BMRN,neutral
174387.0,"Benzinga's Top Upgrades, Downgrades For February 7, 2017",2017-02-07 09:30:00-05:00,BMRN,positive
174388.0,"Morgan Stanley Initiates Coverage On Biomarin Pharmaceutical At Overweight, Announces $110 Price Target",2017-02-07 06:50:00-05:00,BMRN,negative
174389.0,BioMarin Reports Received Access to PRIME Regulatory Support from EMA for BMN 270 in Hemophilia A,2017-02-01 16:20:00-05:00,BMRN,positive
174390.0,BioMarin's Upcoming Catalysts Named By Credit Suisse,2017-01-23 09:57:00-05:00,BMRN,positive
174391.0,"Benzinga's Top Upgrades, Downgrades For January 23, 2017",2017-01-23 09:13:00-05:00,BMRN,positive
174392.0,"Credit Suisse Assumes Biomarin Pharmaceutical at Outperform, Lowers Target to $107.00",2017-01-23 08:25:00-05:00,BMRN,positive
174393.0,Sarepta Soars Following Encouraging Exondys 51 News,2017-01-10 11:38:00-05:00,BMRN,positive
174394.0,BioMarin Announces Update to Positive Interim Results of Open-label Phase 1/2 Study of BMN 270 as Treatment for Severe Hemophilia A at #JPM17,2017-01-08 21:23:00-05:00,BMRN,positive
174395.0,"Incyte, TESARO, BioMarin Shares Lower, Neurocrine Bio Shares Higher; Hearing Jefferies Classified Cos. as 'Most Favored M&A Targets'",2017-01-05 11:48:00-05:00,BMRN,positive
174396.0,13 Emerging Biotechs With Catalysts In 2017,2017-01-03 14:22:00-05:00,BMRN,neutral
174397.0,Biomarin Spiking Higher on Volume,2016-12-21 11:42:00-05:00,BMRN,neutral
174398.0,BioMarin Enrolls First Patentin in Phase Vosoritide Trial,2016-12-12 08:33:00-05:00,BMRN,neutral
174399.0,"Novartis, Biomarin, Alexion Shares All Moving Higher On AstraZeneca Halt",2016-12-09 09:57:00-05:00,BMRN,positive
174400.0,"Barclays Downgrades 5 Biopharma Stocks, Upgrades Pfizer And Alexion",2016-11-29 10:39:00-05:00,BMRN,neutral
174401.0,7 Biggest Price Target Changes For Tuesday,2016-11-29 09:39:00-05:00,BMRN,neutral
174402.0,"Barclays Downgrades Biomarin Pharmaceutical to Equal-Weight, Lowers Target to $105.00",2016-11-29 07:40:00-05:00,BMRN,negative
174403.0,"BioMarin Tells Bloomberg They Will Not Present At ASH Conf., Plan To Update BMN 270 In January",2016-11-17 13:53:00-05:00,BMRN,neutral
174404.0,BioMarin Spikes to High of $92.30 on Volume,2016-11-17 13:47:00-05:00,BMRN,neutral
174405.0,Jefferies London Healthcare Conference Taking Place Today,2016-11-16 10:52:00-05:00,BMRN,neutral
174406.0,Piper Jaffray Thinks It Might Be A Good Time For BioMarin To Sell Itself,2016-11-07 10:19:00-05:00,BMRN,positive
174407.0,Benzinga's Top Downgrades,2016-11-07 09:13:00-05:00,BMRN,positive
174408.0,PiperJaffray Downgrades BioMarin Pharmaceutical Inc. - Common Stock to Neutral,2016-11-07 07:17:00-05:00,BMRN,neutral
174409.0,Biomarin Spokesperson Tells Benzinga They Have 'No Comment' Regarding The Company's Stock Move Today,2016-11-04 11:32:00-04:00,BMRN,negative
174410.0,"Alexion, BioMarin Spike Higher as Traders Circulate Unconfirmed Report Alexion has Cancelled Out of CS Conference",2016-11-04 09:37:00-04:00,BMRN,negative
174411.0,BioMarin Spikes to High of $84.09 on Volume,2016-11-04 09:32:00-04:00,BMRN,neutral
174412.0,Deutsche Bank Initiates Coverage On BioMarin Pharmaceutical Inc. - Common Stock at Buy,2016-11-03 06:05:00-04:00,BMRN,neutral
174413.0,UPDATE: BioMarin Now Raises FY16 non-GAAP Loss Estimate From $30M-$50M To $10M-$30M,2016-10-27 16:07:00-04:00,BMRN,negative
174414.0,BioMarin Raises Guidance,2016-10-27 16:06:00-04:00,BMRN,neutral
174415.0,"BioMarin Reports Q3 GAAP Loss/Share of $0.26 vs Est Loss/Share $0.39, non-GAAP Income Of $3M, Rev $280M vs $289.44M Est",2016-10-27 16:05:00-04:00,BMRN,neutral
174416.0,Goldman Says These 25 Healthcare Stocks Are Immune To The Election,2016-10-24 10:55:00-04:00,BMRN,positive
174417.0,"Solid Biosciences Granted US, EU Orphan Drug Designations for Lead Gene Therapy Candidate for Duchenne Muscular Dystrophy",2016-10-24 06:11:00-04:00,BMRN,positive
174418.0,UPDATE: Biomarin Vosoritide Data Shows Consistent Safety Profile At High Dose With ~50% Increase IN Mean Annualized Growth Velocity,2016-10-19 17:04:00-04:00,BMRN,positive
174419.0,BioMarin Presents Vosoritide Data,2016-10-19 17:02:00-04:00,BMRN,neutral
174420.0,"UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A, Requirement For Prophylactic Corticosteroids Removed",2016-10-13 16:02:00-04:00,BMRN,positive
174421.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-10-13 08:48:00-04:00,BMRN,neutral
174422.0,Rich Ross Shares His Biotech Trades,2016-10-11 06:32:00-04:00,BMRN,positive
174423.0,Wedbush Boosts Target On Sarepta Shares From $66 To $72 Amid US Launch Of Exondys 51,2016-10-10 07:44:00-04:00,BMRN,positive
174424.0,3 Reasons Sarepta Shares Rallied Following News Of $225 Million Offering,2016-09-22 15:22:00-04:00,BMRN,positive
174425.0,Patent Trial And Appeal Board Hands Sarepta Another Big Win,2016-09-21 11:50:00-04:00,BMRN,positive
174426.0,"BioMarin Announces Seeking Review of Ruling in Composition of Matter Patent Interference (No. 106,008)",2016-09-21 08:55:00-04:00,BMRN,neutral
174427.0,"After-Hours Decliners Sept. 20, 2016: MSTX Down 84%, MIRN 29%, BMRN 1%",2016-09-20 18:01:00-04:00,BMRN,neutral
174428.0,Sarepta Shares  Up ~1.4% in After-Hours Trade; BioMarin Shares Indicated Down ~2%,2016-09-20 17:23:00-04:00,BMRN,positive
174429.0,"UPDATE: Sarepta Highlights Key Patent Protection for Eteplirsen, SRP-4053 Remains Valid",2016-09-20 17:18:00-04:00,BMRN,neutral
174430.0,UPDATE: Sarepta Highlights Final Refusal of BioMarin's Interfering Claims Facilitates Commercialization of Etelirsen in US,2016-09-20 17:17:00-04:00,BMRN,neutral
174431.0,"Sarepta Reports Favorable USPTO Decisions in Exon 51, Exon 53 Composition of Matter Patent Interference Cases Against BioMarin",2016-09-20 17:15:00-04:00,BMRN,positive
174432.0,Sarepta Shares Continue Rally As Analysts Flip To Positive,2016-09-20 15:04:00-04:00,BMRN,positive
174433.0,BioMarin Reports EMA Validation of Brineura MAA for Treatment of CLN2 Disease,2016-09-15 08:38:00-04:00,BMRN,neutral
174434.0,SunTrust On Sarepta Therapeutics: FDA Likely To Deny Approval For Eteplirsen,2016-09-14 15:27:00-04:00,BMRN,positive
174435.0,"Biomarin Reports Update On Brineura Program For CLN2 Disease FDA Designates This Submission As A Major Amendment To Application, Extending PDUFA Action Date By 3 Months To Apr. 27th, 2017",2016-09-06 16:07:00-04:00,BMRN,neutral
174436.0,Watch These 7 Huge Call Purchases In Tuesday Trade,2016-08-23 02:25:00-04:00,BMRN,positive
174437.0,Option Alert: BMRN Oct16 110 Calls Sweep: 830 @  Above Ask!  $3.09: 1004 traded vs 401 OI: $95.90 Ref,2016-08-22 09:39:00-04:00,BMRN,positive
174438.0,BioMarin Pharmaceutical +3.27% Premarket @$95.00,2016-08-22 08:35:00-04:00,BMRN,neutral
174439.0,8 Stocks Moving In Monday's Pre-Market Session,2016-08-22 08:13:00-04:00,BMRN,neutral
174440.0,There Have Been 20 Secondary Offerings Over The Last 2 Days,2016-08-09 14:05:00-04:00,BMRN,neutral
174441.0,20 Biggest Mid-Day Losers For Tuesday,2016-08-09 13:15:00-04:00,BMRN,negative
174442.0,BioMarin Prices Offering of 7.5M Shares at $96/Share for Gross Proceeds $720M,2016-08-09 09:04:00-04:00,BMRN,negative
174443.0,22 Stocks Moving In Tuesday's Pre-Market Session,2016-08-09 08:48:00-04:00,BMRN,neutral
174444.0,BioMarin Reports Public Offering of 7.5M  Shares of Common Stock,2016-08-08 16:33:00-04:00,BMRN,positive
174445.0,Biomarin Sees FY16 Rev. $1.1-$1.15B vs. Est. $1.09B,2016-08-04 16:59:00-04:00,BMRN,neutral
174446.0,"BioMarin Reports Q2 EPS $(2.61) vs. Est. $(0.52), Rev. $300.1M vs. Est. $278M",2016-08-04 16:58:00-04:00,BMRN,neutral
174447.0,"BioMarin Sets PDUFA Action Date as Jan. 27, '17",2016-07-27 18:03:00-04:00,BMRN,neutral
174448.0,BioMarin Reports FDA Accepted BLA for Co.'s Cerliponase Alfa for CLN2 Disease,2016-07-27 18:03:00-04:00,BMRN,positive
174449.0,UPDATE: BioMarin Says 'Phase 2b Study to Begin Mid-2017 for Potential Accelerated Approval Filing',2016-07-27 14:33:00-04:00,BMRN,positive
174450.0,"UPDATE: BioMarin Results Demonstrate '6 of 7 High Dose Patients Show Factor VIII levels above 50%, 7th patient above 10%'",2016-07-27 14:32:00-04:00,BMRN,neutral
174451.0,BioMarin Reports PoC Data for BMN 270 Therapy in Hemophilia A: No Clinically Relevant Sustained Rises in ALT,2016-07-27 14:31:00-04:00,BMRN,negative
174452.0,"BioMarin Reports Will Provide Updated Data for BMN 270 in Hemophilia A at XXXII Int'l Congress of World Federation of Meophilia, Will Hold Call to Discuss on Wed., Jul. 27",2016-07-21 16:52:00-04:00,BMRN,neutral
174453.0,Option Alert: BMRN Jul16 95.0 Calls Sweep: 509 @  ASK  $0.40: 511 traded vs 2717 OI:  Earnings 8/1  $89.14 Ref,2016-07-14 13:47:00-04:00,BMRN,positive
174454.0,Option Alert: BMRN Aug16 100 Calls: 650 @  ASK  $5.50: 668 traded vs 2068 OI:  Earnings 8/1  $90.00 Ref,2016-07-08 10:12:00-04:00,BMRN,positive
174455.0,Medivation Bidders Will Have To Price In Talazoparib; BMO Sees $68-$76 Takeout Price,2016-07-07 15:33:00-04:00,BMRN,neutral
174456.0,11 Biggest Mid-Day Gainers For Thursday,2016-07-07 13:00:00-04:00,BMRN,neutral
174457.0,Technical Alert: Bimoarin Pops And Drops After Renewed Interest From Roche,2016-07-07 12:55:00-04:00,BMRN,positive
174458.0,Benzinga's Volume Movers,2016-07-07 10:47:00-04:00,BMRN,neutral
174459.0,"Adam Feuerstein @adamfeuerstein Tweet: @TerryMSmith @Sport234a $BMRN does get royalty on tala sales, so if that $30B mkt opportunity promised by $MDVN comes true… $$$$",2016-07-07 09:52:00-04:00,BMRN,positive
174460.0,12 Stocks Moving In Thursday's Pre-Market Session,2016-07-07 08:27:00-04:00,BMRN,neutral
174461.0,Roche said to have Renewed Interest in BioMarin -Betaville,2016-07-06 18:04:00-04:00,BMRN,positive
174462.0,Betaville's Ben Harrington Says Sanofi Could bid for Biomarin if Medivation Bid Fails,2016-06-27 09:51:00-04:00,BMRN,negative
174463.0,BioMarin Reports Acceptance of Late-Breaking Abstract for BMN 270 at WFH World Congress,2016-06-20 16:38:00-04:00,BMRN,positive
174464.0,Wedbush Analyst Says Sanofi Could Not Feasibly Drop Its Bid For Medivation To Shift Sight To Biomarin,2016-06-17 12:40:00-04:00,BMRN,positive
174465.0,15 Stocks Moving In Friday's Pre-Market Session,2016-06-17 08:18:00-04:00,BMRN,neutral
174466.0,BiomMarin +3.9% Premarket @$84.00,2016-06-17 08:09:00-04:00,BMRN,neutral
174467.0,BioMarin IR Says Suspension of Recruitment in BMN 270 Trial Was Announced on April 20th at R&D Day; One Patient had Elevated Liver Enzymes,2016-06-16 11:52:00-04:00,BMRN,neutral
174468.0,Adam Feuerstein @adamfeuerstein $BMRN — StreetAccount notes company previously disclosed temporary enrollment suspension in '270 hemophilia study.,2016-06-16 10:22:00-04:00,BMRN,neutral
174469.0,Biomarin Shares Selling Off; Traders Attributing to Report Co has Suspended Recruitment in BMN 270 Trial,2016-06-16 09:39:00-04:00,BMRN,negative
174470.0,BioMarin Pharmaceutical Gene Therapy Study in Severe Haemophilia A Patients Suspended Participant Recruitment,2016-06-16 09:39:00-04:00,BMRN,negative
174471.0,BioMarin Shares Fall ~$3.50 Over Last Few Mins,2016-06-16 09:38:00-04:00,BMRN,positive
174472.0,6 Largest Price Target Changes For Monday,2016-06-13 09:32:00-04:00,BMRN,neutral
174473.0,Credit Suisse Cuts BioMarin Price Target As Company Gives Up Revenue For Profit,2016-06-13 08:15:00-04:00,BMRN,positive
174474.0,There's Hope For BioMarin Beyond Kyndrisa,2016-06-03 09:36:00-04:00,BMRN,positive
174475.0,Biomarin Shares +5% @$91.84; Traders Attributing to Negative News for Sarepta on  Final Individual Patient Expanded Acess Form Being Considered Positive for Biomarin,2016-06-02 10:20:00-04:00,BMRN,positive
174476.0,Goldman Sachs Still Bullish On BioMarin Pipeline Despite Kyndrisa Pullout,2016-06-01 09:55:00-04:00,BMRN,neutral
174477.0,BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa (drisapersen) in Europe,2016-05-31 16:07:00-04:00,BMRN,neutral
174478.0,"BioMarin Reports EMA Grants Accelerated Assessment for Cerliponase Alfa, Co. Seeks Priority Review In U.S.",2016-05-03 08:25:00-04:00,BMRN,positive
174479.0,BioMarin Sees FY16 Rev. $1.05-$1.1B vs. Est. $1.09B,2016-04-28 16:19:00-04:00,BMRN,neutral
174480.0,"BioMarin Reports Q1 EPS $(0.53) vs. Est. $(0.79), Rev. $236.7M vs. Est. $240.45M",2016-04-28 16:19:00-04:00,BMRN,neutral
174481.0,"Short Sellers Dump Vertex, Load Up On Baxalta",2016-04-28 08:34:00-04:00,BMRN,negative
174482.0,"Biomarin Shares Spiking, DealReporter Says Co May Be Attractive To Sanofi",2016-04-22 15:28:00-04:00,BMRN,positive
174483.0,BioMarin Says BMN 250 has been Granted Orphan Drug Designation by EC,2016-04-21 16:38:00-04:00,BMRN,positive
174484.0,BioMarin Reports Enrollment of First Patient in Phase 1/2 Trial of BMN 250 for Treatment of MPS IIIB,2016-04-21 16:33:00-04:00,BMRN,neutral
174485.0,BioMarin Pharmaceutical Stock Rises On Favorable Phase 2 Study Of Vosoritide,2016-04-20 11:11:00-04:00,BMRN,positive
174486.0,BioMarin Provides Program Update on Vosoritide in Achondroplasia,2016-04-20 10:37:00-04:00,BMRN,neutral
174487.0,"BioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy Program, 2 High Dose Patients Showing Increasing Levels Of Factor VII Above 50%",2016-04-20 08:33:00-04:00,BMRN,positive
174488.0,Adam Feuerstein @adamfeuerstein Tweet: $BMRN R&D event tomorrow. First airing of human data from its hemophilia A gene therapy program.,2016-04-19 11:35:00-04:00,BMRN,neutral
174489.0,Chardan Analyst: Amicus Therapeutics Could Be Bought For $22.50/Share,2016-04-12 09:44:00-04:00,BMRN,neutral
174490.0,BMO Capital Initiates Coverage on Biomarin Pharmaceutical at Outperform,2016-04-07 06:29:00-04:00,BMRN,neutral
174491.0,"BioMarin Receives European Orphan Drug Designation for BMN 270, Currently Conducting Phase 1/2 Study To Evaluate Safety, Efficacy Of BMN 270 In Hemophilia A",2016-03-24 08:33:00-04:00,BMRN,positive
174492.0,"Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Lowers PT to $109.00",2016-03-22 07:31:00-04:00,BMRN,positive
174493.0,BioMarin Announces Phase 3 Pegvaliase Study Meets Primary Endpoint,2016-03-21 06:03:00-04:00,BMRN,neutral
174494.0,BioMarin Announces Phase 3 Study of Pegvaliase for Phenylketonuria Meets Primary Endpoint of Blood Phenylalanine  Reduction (p<0.0001),2016-03-21 06:02:00-04:00,BMRN,neutral
174495.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-03-11 16:19:00-05:00,BMRN,neutral
174496.0,Baird Buying Ultragenyx And BioMarin,2016-03-08 13:54:00-05:00,BMRN,neutral
174497.0,"Baird Upgrades Biomarin Pharmaceutical to Outperform, Raises PT to $110.00",2016-03-07 16:13:00-05:00,BMRN,neutral
174498.0,Goldman Sachs Upgrades Biomarin Pharmaceutical to Conviction Buy,2016-03-07 07:37:00-05:00,BMRN,neutral
174499.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-03-04 16:21:00-05:00,BMRN,neutral
174500.0,"Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Raises PT to $114.00",2016-03-03 08:09:00-05:00,BMRN,positive
174501.0,"BioMarin Receives Orphan Drug Designation From FDA for First AAV-Factor VIII Gene Therapy, BMN 270, for Patients With Hemophilia A",2016-03-01 17:57:00-05:00,BMRN,neutral
174502.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-03-01 17:00:00-05:00,BMRN,neutral
174503.0,Earlier 8-K from BioMarin Showed Interim Conclusion from Phase 1/2 Study of BMN 190 in Children with CLN2 Disease 'Well-Tolerated' and 'Slows Progression of Functional Decline in Children,2016-03-01 15:30:00-05:00,BMRN,neutral
174504.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-02-29 16:36:00-05:00,BMRN,neutral
174505.0,"BioMarin Rebrands RareConnections, Consolidating Co.'s Comprehensive Support, Services for Eligible Rare Disease Patients",2016-02-29 08:38:00-05:00,BMRN,positive
174506.0,"The Stocks That Moved The S&P, Dow And Nasdaq Today",2016-02-26 16:35:00-05:00,BMRN,neutral
174507.0,"RBC Capital Maintains Outperform on Biomarin Pharmaceutical, Lowers PT to $125.00",2016-02-26 06:52:00-05:00,BMRN,negative
174508.0,"Barclays Maintains Overweight on Biomarin Pharmaceutical, Lowers PT to $105.00",2016-02-26 05:40:00-05:00,BMRN,negative
174509.0,Biomarin Sees FY16 Rev. $1.05-$1.1B vs. Est. $1.15B,2016-02-25 16:04:00-05:00,BMRN,neutral
174510.0,"BioMarin Reports Q4 EPS $0.39 vs. Est. $0.99, Rev. $227.9M vs. Est. $224.38M",2016-02-25 16:03:00-05:00,BMRN,neutral
174511.0,"Leerink Swann Maintains Outperform on Biomarin Pharmaceutical, Lowers PT to $120.00",2016-02-23 07:53:00-05:00,BMRN,negative
174512.0,"Oppenheimer Maintains Perform on Biomarin Pharmaceutical, Lowers PT to $99.00",2016-02-23 07:53:00-05:00,BMRN,negative
174513.0,"BioMarin's Carnage Could Be Buying Opportunity, Says Stifel",2016-02-16 11:06:00-05:00,BMRN,positive
174514.0,Stifel Nicolaus Upgrades Biomarin Pharmaceutical to Buy,2016-02-16 06:51:00-05:00,BMRN,neutral
174515.0,"Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Catalysts",2016-02-08 15:27:00-05:00,BMRN,neutral
174516.0,The FDA Just Crushed Sarepta Therapeutics' Hopes Of Releasing A Muscular Dystrophy Drug,2016-01-21 11:23:00-05:00,BMRN,neutral
174517.0,Why BioMarin's Pipeline Could Be Worth $4 Billion-Plus,2016-01-20 14:31:00-05:00,BMRN,positive
174518.0,Credit Suisse Bullish On Most Big Pharma Names,2016-01-20 10:34:00-05:00,BMRN,positive
174519.0,"Credit Suisse Initiates BMRN At Outperform, Focus Is Primarily On The Pipeline Potentially Worth Unadjusted ~$4.1B, Says Re-Acquiring Rights For PKU Franchise 'was the right strategic move'",2016-01-20 05:53:00-05:00,BMRN,positive
174520.0,"Credit Suisse Initiates Coverage on Biomarin Pharmaceutical at Outperform, Announces $110.00 PT",2016-01-19 16:15:00-05:00,BMRN,positive
174521.0,UPDATE: BioMarin Highlights Kyndrisa MAA Remains Under Regulatory Review in Europe,2016-01-14 08:31:00-05:00,BMRN,neutral
174522.0,BioMarin Reports FDA Issued CRL Related to Kyndrisa for DMD Amendable to Exon 51 Skipping,2016-01-14 08:31:00-05:00,BMRN,neutral
174523.0,Adam Feuerstein Tweets: $BMRN says 2016 revenue will exceed $1B with or without drisapersen. Current consensus $1.2B #JPM16,2016-01-11 11:36:00-05:00,BMRN,neutral
174524.0,"BioMarin Announces Interim Analysis of INSPIRE Clinical Trial in Pompe Disease, Encouraged By Positive Trends In Trial",2016-01-11 11:35:00-05:00,BMRN,positive
174525.0,8-K Filing Shows BioMarin Pharma Amended Kuvan Agreement With Ares Trading,2015-12-28 14:30:00-05:00,BMRN,positive
174526.0,BioMarin Announces That FDA Has Advised it Will Not Take Action on the Kyndrisa™ (drisapersen) New Drug Application by the PDUFA Date,2015-12-18 08:30:00-05:00,BMRN,neutral
174527.0,Wedbush Offers Probabilities For Upcoming Catalysts In Emerging Pharmas,2015-12-08 08:29:00-05:00,BMRN,neutral
174528.0,"Wedbush's Moussatos Offers Probabilities for Upcoming Catalysts in Emerging Pharma Sector Heading Into '16: Discusses 14 Cos., Including BioMarin, Intercept, Regulus, Relypsa, Vitae, Xoma",2015-12-07 13:07:00-05:00,BMRN,neutral
174529.0,"BioMarin Pharma Crashed This Week, So Why Is This Mega-Bank Still Bullish?",2015-11-25 10:43:00-05:00,BMRN,neutral
174530.0,"Biomarin Resumes Trade At $90/Share, Spiking Higher",2015-11-25 07:10:00-05:00,BMRN,neutral
174531.0,BioMarin Pharmaceutical to Resume Trading at 7:10 AM ET,2015-11-25 06:48:00-05:00,BMRN,neutral
174532.0,FDA Advisory Committee Discusses Clinical Data Package for BioMarin's  Kyndrisa for Treatment of Duchenne Muscular Dystrophy  Amenable to Exon 51 Skipping,2015-11-24 19:36:00-05:00,BMRN,neutral
174533.0,Volume Spike in Sarepta on Report of FDA Panel Vote on BioMarin DMD Treatment,2015-11-24 15:10:00-05:00,BMRN,neutral
174534.0,UPDATE:  7 of 17 FDA Panel Members Vote That Strength Of Efficacy Evidence Of Drisapersen In Study 1 Has No Effect On The Persuasiveness Of The Study,2015-11-24 15:08:00-05:00,BMRN,positive
174535.0,9 of 17 FDA Panel Members Vote That Strength Of Efficacy Evidence Of BioMarin's Drisapersen In Study 1 Weakens The Persuasiveness Of The Study,2015-11-24 15:08:00-05:00,BMRN,positive
174536.0,BioMarin Posts Presentation at FDA Advisory Committee Meeting,2015-11-24 10:07:00-05:00,BMRN,neutral
174537.0,"UPDATE: BioMarin Releases PR Confirming Stock Is Halted, FDA Meeting To Review NDA For Kyndrisa For Duchenne Muscular Dystrophy",2015-11-24 07:09:00-05:00,BMRN,neutral
174538.0,"BioMarine Pharma Halted, T-1 News Pending",2015-11-24 07:03:00-05:00,BMRN,neutral
174539.0,Oppenheimer On Upcoming BioMarin Panel: Efficacy Concerns Circulate,2015-11-23 14:30:00-05:00,BMRN,neutral
174540.0,NICE Recommends BioMarin's Vimizim for the Treatment of Morquio A Syndrome in England,2015-11-23 10:42:00-05:00,BMRN,positive
174541.0,Barron's Recap: 16 All-Star Women Financial Advisors,2015-11-22 10:39:00-05:00,BMRN,neutral
174542.0,Here's Why Sarepta Is Skyrocketing While BioMarin Is Falling,2015-11-20 10:19:00-05:00,BMRN,negative
174543.0,Morning Market Losers,2015-11-20 10:06:00-05:00,BMRN,negative
174544.0,"Sarepta Moving In Contrast To Biomarin In Pre-Market After Competing Drug Biomarin's Kyndrisa Data Analysis And Briefing Documents Released, Up From ~$26/Share To $32.71/Share",2015-11-20 08:38:00-05:00,BMRN,neutral
174545.0,"Biomarin Falls From $103.13/Share To Low Of $88.50/Share On FDA Briefing Documents And Analysis Of Kyndrisa, Now Trading Up To $95/Share",2015-11-20 08:20:00-05:00,BMRN,negative
174546.0,Benzinga's Top #PreMarket Losers,2015-11-20 08:17:00-05:00,BMRN,negative
174547.0,Release Confirms BioMarin Announces Data Analysis Demonstrating Consistent Efficacy of Kyndrisa in Comparable Patients Across Three Randomized Studies,2015-11-20 08:12:00-05:00,BMRN,neutral
174548.0,Biomarin Release Confirms FDA Posts Briefing Documents for Advisory Committee Meeting to Review Kyndrisa for the Potential Treatment of Duchenne Muscular Dystrophy Amendable to Exon 51 Skipping,2015-11-20 08:10:00-05:00,BMRN,neutral
174549.0,Shares of BioMarin Indicated Down ~11%+ Following FDA Staff Review Related to Co.'s Drisapersen,2015-11-20 08:09:00-05:00,BMRN,positive
174550.0,Goldman Sees 2016 'Flight To Quality' In These Biotech Stocks,2015-11-18 11:05:00-05:00,BMRN,neutral
174551.0,Benzinga's Top Initiations,2015-11-18 09:34:00-05:00,BMRN,positive
174552.0,"Oppenheimer Initiates Coverage on Biomarin Pharmaceutical at Perform, Announces $119.00 PT",2015-11-18 09:13:00-05:00,BMRN,neutral
174553.0,"Goldman Sachs Initiates Coverage on Biomarin Pharmaceutical at Buy, Announces $158.00 PT",2015-11-18 06:44:00-05:00,BMRN,neutral
174554.0,"Oppenheimer Initiates Coverage on Biomarin Pharmaceutical at Perform, Announces $119.00 PT",2015-11-17 17:41:00-05:00,BMRN,neutral
174555.0,"Positive FDA Panel Vote Could Be Coming For BioMarin Pharma, Research Says",2015-11-13 09:53:00-05:00,BMRN,positive
174556.0,BioMarin Reports Q3 GAAP Loss of $0.60/Share vs Loss of $0.65/Share Est.,2015-10-29 16:04:00-04:00,BMRN,negative
174557.0,"Biotech ETFs: Buy, Buy, Buy?",2015-10-27 07:19:00-04:00,BMRN,neutral
174558.0,Cowen: In Biotech Earnings We Trust,2015-10-19 10:02:00-04:00,BMRN,positive
174559.0,BioMarin Reports FDA Advisory Committee to Review Drisapersen for Treatment of Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping,2015-10-15 07:57:00-04:00,BMRN,neutral
174560.0,BioMarin's Initial 6-Month Data From Phase 2 Study of Vosoritide (BMN 111) in Children With Achondroplasia Presented at the American Society for Bone and Mineral Research Annual 2015 Meeting,2015-10-12 16:30:00-04:00,BMRN,neutral
174561.0,"Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now",2015-10-06 14:08:00-04:00,BMRN,neutral
174562.0,"BioMarin to Acquire Rights to Phenylketonuria Franchise From Merck Serono for Upfront Payment of €340M, Plus Milestones",2015-10-01 04:23:00-04:00,BMRN,neutral
174563.0,"Wednesday's After-Hours Movers: PBF Energy, BioMarin Pharmaceutical And More",2015-09-30 16:42:00-04:00,BMRN,positive
174564.0,BioMarin to Present Research Results on Duchenne Muscular Dystrophy and Pompe Disease Programs at the 20th International Congress of the World Muscle Society,2015-09-30 16:06:00-04:00,BMRN,neutral
174565.0,Benzinga's Top #PreMarket Losers,2015-09-30 08:31:00-04:00,BMRN,negative
174566.0,Sarepta Reports US PTO Decision inPatent Interference Case with BioMarin,2015-09-30 07:04:00-04:00,BMRN,neutral
174567.0,BioMarin Enrolls Initial Patient in Phase 1/2 Trial of Gene Therapy Drug Candidate BMN 270 for the Treatment of Hemophilia A,2015-09-28 16:09:00-04:00,BMRN,neutral
174568.0,BioMarin Reports Kuvan Patent Challenge Settlement,2015-09-18 16:30:00-04:00,BMRN,positive
174569.0,What It's Like To Have Dinner With BioMarin Executives,2015-09-16 16:17:00-04:00,BMRN,positive
174570.0,Amgen And Biogen Lead Short Interest Surge In Biotechs,2015-09-14 16:01:00-04:00,BMRN,positive
174571.0,UBS: Biotech Will Continue To Outperform In 2015,2015-09-08 13:22:00-04:00,BMRN,neutral
174572.0,BioMarin Announces Two Oral and 19 Poster Presentations at the Society for the Study of Inborn Errors of Metabolism 2015 Annual Meeting,2015-08-31 08:33:00-04:00,BMRN,negative
174573.0,Option Alert: $BMRN Jan $140 Call; 1232 Contracts @Ask @$11.70; Now $122.14,2015-08-25 15:47:00-04:00,BMRN,positive
174574.0,"Benzinga's M&A Chatter for Monday August 24, 2015",2015-08-24 18:44:00-04:00,BMRN,neutral
174575.0,"Piper Jaffray Goes Overweight Sarepta, Expects FDA To Accept Next Key Drug Filing",2015-08-24 11:29:00-04:00,BMRN,neutral
174576.0,"Medivation Announces Acquisition of Worldwide Rights to Talazoparib from BioMarin, Will Pay $410M Upfront",2015-08-24 07:01:00-04:00,BMRN,negative
174577.0,"Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib, a Potent PARP Inhibitor, From BioMarin",2015-08-24 07:00:00-04:00,BMRN,positive
174578.0,"In new note to subscribers, CMT Christian Tharp making bet that 15-20% correction is coming",2015-08-21 15:39:00-04:00,BMRN,neutral
174579.0,UBS Analysts Might've Found Another BioMarin Catalyst,2015-08-21 09:41:00-04:00,BMRN,neutral
174580.0,Treating Female Sexual Dysfunction (And How To Invest In It),2015-08-19 16:59:00-04:00,BMRN,negative
174581.0,BioMarin Receives Rare Pediatric Disease Designation From FDA for Drisapersen for the Potential Treatment of Duchenne Muscular Dystrophy,2015-08-19 16:08:00-04:00,BMRN,neutral
174582.0,Why Two Wall Street Titans Love BioMarin Pharma,2015-08-04 09:17:00-04:00,BMRN,positive
174583.0,"Biomarin Q2 Loss $0.51 vs Loss $0.53, Sales $250.5M",2015-08-03 16:04:00-04:00,BMRN,negative
174584.0,"With The Teva Money, Allergan Could Engage In 'Large M&A' Next: Evercore ISI",2015-07-27 16:25:00-04:00,BMRN,positive
174585.0,"Evercore ISI says Allergan may now engage in ""large M&A,"" buyside survey indicates Biogen, AbbVie, BioMarin, or a combination with Pfizer as possible takeout targets.",2015-07-27 15:46:00-04:00,BMRN,positive
174586.0,UPDATE: BioMarin Says ABRAZO Phase 2 Trial Met Protocol-Specified Threshold,2015-07-20 08:32:00-04:00,BMRN,neutral
174587.0,BioMarin Gives Program Update for Talazoparib in Metastatic Breast Cancer,2015-07-20 08:32:00-04:00,BMRN,negative
174588.0,Short Sellers Shy Away From Biotech Stocks,2015-07-13 09:54:00-04:00,BMRN,negative
174589.0,BioMarin Reports FDA Accepts Drisapersen NDA for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping,2015-06-29 08:30:00-04:00,BMRN,positive
174590.0,Biomarin Announced EMA Validates MAA For Drisapersen For Treatment Of Duchenne Muscular Dystrophy Amendable To Exon 51 Skipping,2015-06-25 16:04:00-04:00,BMRN,positive
174591.0,Baird Downgrades BioMarin Pharmaceutical To  Neutral,2015-06-19 10:31:00-04:00,BMRN,neutral
174592.0,Benzinga's Volume Movers,2015-06-19 10:31:00-04:00,BMRN,neutral
174593.0,Benzinga's Top Downgrades,2015-06-19 10:08:00-04:00,BMRN,positive
174594.0,Baird Downgrades Biomarin Pharmaceutical to Neutral,2015-06-19 06:43:00-04:00,BMRN,neutral
174595.0,"Daily Movers: Welcoming Fitbit; BioMarin Soars Again, While Oracle Slumps",2015-06-18 16:21:00-04:00,BMRN,positive
174596.0,Mid-Afternoon Market Update: BioMarin Pharmaceutical Jumps Following Announcement Of Positive BMN 111 Data; Jabil Circuit Shares Fall,2015-06-18 15:32:00-04:00,BMRN,positive
174597.0,Mid-Day Market Update: Oracle Drops On Downbeat Results; Radius Health Shares Surge,2015-06-18 13:31:00-04:00,BMRN,positive
174598.0,BioMarin's Results Are In: What Do They Mean?,2015-06-18 10:31:00-04:00,BMRN,neutral
174599.0,Mid-Morning Market Update: Markets Open Higher; Kroger Earnings Beat Views,2015-06-18 10:22:00-04:00,BMRN,neutral
174600.0,Benzinga's Volume Movers,2015-06-18 10:21:00-04:00,BMRN,neutral
174601.0,Morning Market Gainers,2015-06-18 09:39:00-04:00,BMRN,neutral
174602.0,UPDATE: BioMarin Shares Rise 9% Premarket Following Announcement of Positive BMN 111 Data,2015-06-18 08:13:00-04:00,BMRN,positive
174603.0,Benzinga's Top #PreMarket Gainers,2015-06-18 08:12:00-04:00,BMRN,positive
174604.0,"Pier 1, BioMarin, HomeAway & Oracle Lead Wednesday's After-Hours Movers",2015-06-17 17:39:00-04:00,BMRN,neutral
174605.0,BioMarin Shares Rise 9.5% After-Hours Following Announcement of Positive BMN 111 Data,2015-06-17 16:11:00-04:00,BMRN,positive
174606.0,BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study,2015-06-17 16:05:00-04:00,BMRN,positive
174607.0,SunTrust's 5 Biotech Picks For The Next 6 Months,2015-06-17 13:24:00-04:00,BMRN,neutral
174608.0,Is BioMarin A Buy Ahead Of This Important Data Release?,2015-06-15 10:44:00-04:00,BMRN,positive
174609.0,"Adam Feuerstein ‏tweets  ""FDA DMD guidance is + for $BMRN (if you are a $BMRN supporter) FDA DMD guidance is + for $SRPT (if you are a $SRPT supporter.)""",2015-06-09 11:22:00-04:00,BMRN,neutral
174610.0,BioMarin Submits Drisapersen MAA to EMA for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping,2015-06-08 08:37:00-04:00,BMRN,neutral
174611.0,BioMarin Gives Drisapersen MAA to EMA for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping,2015-06-08 08:31:00-04:00,BMRN,neutral
174612.0,Benzinga's Top Initiations,2015-06-05 10:04:00-04:00,BMRN,positive
174613.0,Barclays Initiates BioMarin Pharmaceutical With Overweight,2015-06-05 08:39:00-04:00,BMRN,negative
174614.0,"Barclays: BioMarin Is A Buy, Sees $150/Share",2015-06-05 07:26:00-04:00,BMRN,neutral
174615.0,"Barclays Initiates Coverage on Biomarin Pharmaceutical at Overweight, Announces $150.00 PT",2015-06-05 04:34:00-04:00,BMRN,negative
174616.0,"CHMP Gave Six Recommendations on Extensions of Therapeutic Indication for: Janssen's Simponi and Stelara, Pharmacyclics' Imbruvica, Eisai's Fycompa, BioMarin's Kuvan, Novo's Xultophy",2015-05-22 07:11:00-04:00,BMRN,neutral
174617.0,"The Street Sweeper Tweets: ""$SRPT up on FDA plan. Long way to go.Canaccord says if $BMRN's drug is approved 1st, pressure to approve SRPT ""may decrease."" We're short.""",2015-05-20 15:39:00-04:00,BMRN,positive
174618.0,Is BioMarin Still An Outperform At This Research Firm?,2015-05-01 11:05:00-04:00,BMRN,neutral
174619.0,"BioMarin Pharma Reports Q1 Adj EPS -$0.16, GAAP EPS -$0.43 Vs Est -$0.53, Sales $203.3M Vs Est $202.82M, Sees 2015 Revs $850M-$880",2015-04-30 16:20:00-04:00,BMRN,neutral
174620.0,BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping,2015-04-27 09:44:00-04:00,BMRN,neutral
174621.0,BioMarin Presents Data on Duchenne Muscular Dystrophy at the 67th American Academy of Neurology Annual Meeting,2015-04-23 16:54:00-04:00,BMRN,neutral
174622.0,Wedbush: BioMarin Pharma Still Worth $104/Share,2015-04-23 06:41:00-04:00,BMRN,positive
174623.0,BioMarin Pharmaceutical Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4),2015-04-21 16:10:00-04:00,BMRN,positive
174624.0,16 Biotech Catalysts SunTrust Is Tracking,2015-04-06 19:38:00-04:00,BMRN,neutral
174625.0,"QuickLogic, Sonic Corp, BioMarin Pharmaceutical Lead Wednesday's After-Hours Movers",2015-04-01 21:31:00-04:00,BMRN,neutral
174626.0,Hearing Deal Reporter Saying BioMarin Not in  Active Takeover Talks,2015-03-31 13:59:00-04:00,BMRN,negative
174627.0,"BioMarin Tells Benzinga They Will be Attending DB Conference on May 5 in Boston, They Have Not Cancelled Any Conferences",2015-03-30 12:32:00-04:00,BMRN,positive
174628.0,Hearing BioMarin has Cancelled Out of Upcoming Conferences,2015-03-30 12:29:00-04:00,BMRN,negative
174629.0,"BioMarin Reports One Oral, Seven Poster Presentations at ACMGG Annual Meeting",2015-03-30 09:07:00-04:00,BMRN,neutral
174630.0,Why BioMarin Pharmaceutical Is Surging,2015-03-27 11:22:00-04:00,BMRN,neutral
174631.0,Benzinga's Volume Movers,2015-03-27 10:27:00-04:00,BMRN,neutral
174632.0,Stocks Hitting 52-Week Highs,2015-03-27 10:15:00-04:00,BMRN,neutral
174633.0,Morning Market Gainers,2015-03-27 09:43:00-04:00,BMRN,neutral
174634.0,UPDATE: Deutsche Bank Analyst on BioMarin Sees 'Potential M&A Take Out in One Year ~$194-$271/Share',2015-03-27 09:19:00-04:00,BMRN,neutral
174635.0,Benzinga's Top #PreMarket Gainers,2015-03-27 08:20:00-04:00,BMRN,positive
174636.0,"UPDATE:  BioMarin Shares Rise 8% Premarket on Rumor of Shire Interest, Deutsche Bank Raising PT to $140 from $90",2015-03-27 07:24:00-04:00,BMRN,positive
174637.0,BioMarin Shares Rise ~7% on Blog Report Indicating Potential Bid from Shire,2015-03-27 07:04:00-04:00,BMRN,positive
174638.0,Is It Closing Time At The Biotech Bar?,2015-03-26 13:45:00-04:00,BMRN,neutral
174639.0,What's Causing The Rally In BioMarin? CEO Answers,2015-03-23 14:47:00-04:00,BMRN,neutral
174640.0,"Myriad, BioMarin Expand Collaboration to Evaluate myChoice HRD as a Companion Diagnostic for Talazoparib",2015-03-17 07:06:00-04:00,BMRN,positive
174641.0,Short Sellers Still Attracted To Biotech Stocks,2015-03-13 12:17:00-04:00,BMRN,positive
174642.0,18 Biotech Stocks These Wall Street Analysts Are Tracking,2015-03-11 12:04:00-04:00,BMRN,neutral
174643.0,"Biotech M&A Outlook Boosted By AbbVie Deal, Says This RBC Analyst",2015-03-05 16:02:00-05:00,BMRN,positive
174644.0,What Evercore Is Watching At BioMarin Pharmaceutical,2015-02-25 17:17:00-05:00,BMRN,neutral
174645.0,"BioMarin Reports Q4 Loss of $0.47/Share vs Loss of $0.58/Share Est., Sales $230.9M vs $190M Est.",2015-02-25 16:03:00-05:00,BMRN,negative
174646.0,"Benzinga's M&A Chatter for Monday February 23, 2015",2015-02-23 17:31:00-05:00,BMRN,neutral
174647.0,"Update: Biomarin, Shire Potential Buyers for PTC Therapeutics, According to Sources -Reuters",2015-02-23 12:30:00-05:00,BMRN,neutral
174648.0,Adam Feuerstein @adamfeuerstein Tweet: $BMRN is interested in buying $PTCT? That's hard to believe.,2015-02-23 12:23:00-05:00,BMRN,positive
174649.0,"BioMarin To Report Revenue In-line With Consensus, Wedbush Says",2015-02-20 17:03:00-05:00,BMRN,neutral
174650.0,Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' Of Drug Approval,2015-02-17 13:54:00-05:00,BMRN,positive
174651.0,"BoiMarin Reports Final Results of Tender Offer for Prosensa's Shares, Closing of Subsequent Offering Period",2015-01-30 08:01:00-05:00,BMRN,positive
174652.0,BioMarin Prices 8.5M Share Offering @$93.25/Share,2015-01-22 04:48:00-05:00,BMRN,positive
174653.0,BioMarin Announces 7.25M Share Public Offering of Common Stock,2015-01-21 16:02:00-05:00,BMRN,positive
174654.0,State Of The Union Lights Up Biotech,2015-01-21 06:25:00-05:00,BMRN,neutral
174655.0,Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical,2015-01-16 15:34:00-05:00,BMRN,positive
174656.0,BioMarin Reports Closing of Tender Offer for Prosensa's Shares,2015-01-15 08:01:00-05:00,BMRN,positive
174657.0,UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical On Positive Preliminary BMN-190 Data,2015-01-14 07:08:00-05:00,BMRN,positive
174658.0,"UPDATE: BioMarin Pharmaceutical Reports in All 9 of Patients Followed for 6-15 Months, Treatment Appears to Show Stabiliazation of Disease",2015-01-12 13:47:00-05:00,BMRN,neutral
174659.0,BioMarin Provides Positive Preliminary Data From Ongoing Phase 1/2 Pivotal Study of BMN 190,2015-01-12 13:46:00-05:00,BMRN,positive
174660.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1,2015-01-12 08:55:00-05:00,BMRN,neutral
174661.0,What Investors Are Looking For In NPS Pharmaceuticals Ahead Of A Potential Sale,2015-01-06 12:34:00-05:00,BMRN,neutral
174662.0,"Monday Social Sentiment Roundup: PNC Financial, Manitowoc, BioMarin Pharmaceutical Are All Moving",2014-12-29 10:12:00-05:00,BMRN,neutral
174663.0,BioMarin Reports Approval of VIMIZIM in Japan,2014-12-29 08:00:00-05:00,BMRN,positive
174664.0,UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical On Path To Long-Term Upside,2014-12-11 10:04:00-05:00,BMRN,positive
174665.0,"FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB",2014-12-10 08:05:00-05:00,BMRN,positive
174666.0,"BioMarin Reports FDA Granted Orphan Drug Designation for NAGLU Fusion Protein, BMN, 250, for Treatment of MPS IIIB",2014-12-10 08:05:00-05:00,BMRN,positive
174667.0,"BioMarin Will Report Breadth of Innovative Development Pipeline at Analyst, Investor Day",2014-12-09 08:05:00-05:00,BMRN,positive
174668.0,BioMarin's VIMIZIM Approved by Australian Therapeutic Goods Administration for Treatment of Morquio A Syndrome,2014-12-07 16:12:00-05:00,BMRN,positive
174669.0,"BioMarin Shares Volatile Following Appearance by CEO Bienaime on CNBC's Fast Money, Discussed Prospects for Prosensa Deal, Drug Approval",2014-12-03 17:35:00-05:00,BMRN,positive
174670.0,BioMarin's MPS IIIB Treatment Receives FDA Orphan Drug Designation,2014-11-26 10:05:00-05:00,BMRN,neutral
174671.0,"Benzinga's M&A Chatter for Monday November 24, 2014",2014-11-24 20:20:00-05:00,BMRN,neutral
174672.0,Mid-Afternoon Market Update: Trina Solar Drops After Quarterly Results; Tetraphase Pharmaceuticals Shares Spike Higher,2014-11-24 15:26:00-05:00,BMRN,positive
174673.0,Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters Shares Jump On Acquisition News,2014-11-24 13:55:00-05:00,BMRN,neutral
174674.0,Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire Prosensa For $17.75/Share,2014-11-24 11:54:00-05:00,BMRN,neutral
174675.0,Benzinga's Volume Movers,2014-11-24 10:28:00-05:00,BMRN,neutral
174676.0,Stocks Hitting 52-Week Highs,2014-11-24 10:18:00-05:00,BMRN,neutral
174677.0,Morning Market Movers,2014-11-24 09:46:00-05:00,BMRN,neutral
174678.0,BioMarin Pharmaceuticals To Acquire Prosensa,2014-11-24 09:06:00-05:00,BMRN,neutral
174679.0,Benzinga's Top #PreMarket Gainers,2014-11-24 08:10:00-05:00,BMRN,positive
174680.0,US Stock Futures Up Ahead Of Economic Data,2014-11-24 07:20:00-05:00,BMRN,neutral
174681.0,Prosensa Holding Shares Rise 61% Premarket on BioMarin Acquisition Announcement; Sarepta Shares Up 11%,2014-11-24 07:18:00-05:00,BMRN,positive
174682.0,BioMarin to Acquire Prosensa for $17.75/Share,2014-11-24 06:02:00-05:00,BMRN,neutral
174683.0,BioMarin to Pay Up to $840M for Prosensa,2014-11-24 06:00:00-05:00,BMRN,negative
174684.0,Stocks Hitting 52-Week Highs,2014-11-10 10:17:00-05:00,BMRN,neutral
174685.0,Benzinga's Top Upgrades,2014-11-10 09:17:00-05:00,BMRN,positive
174686.0,Goldman Sachs Upgrades BioMarin Pharmaceutical To Buy,2014-11-10 08:09:00-05:00,BMRN,neutral
174687.0,"Goldman Sachs Upgrades BioMarin Pharmaceutical Inc. to Buy, Raises PT to $104.00",2014-11-10 05:36:00-05:00,BMRN,neutral
174688.0,"Wedbush Maintains Neutral on BioMarin Pharmaceutical Inc., Raises PT to $77.00",2014-10-27 06:54:00-04:00,BMRN,neutral
174689.0,BioMarin Pharmaceutical Reported Q3 Adj. Net Loss $0.16 Per Share,2014-10-23 16:07:00-04:00,BMRN,neutral
174690.0,BioMarin Pharmaceutical Inc. Reports Q3 EPS of $0.50 vs $(0.22) Est,2014-10-23 16:07:00-04:00,BMRN,neutral
174691.0,"Benzinga's M&A Chatter for Tuesday October 21, 2014",2014-10-21 20:34:00-04:00,BMRN,neutral
174692.0,Biomarin Pharmaceutical Shares Rise 3% as Adam F Mentions it as Possible Shire Target,2014-10-21 09:51:00-04:00,BMRN,positive
174693.0,BioMarin Reports FDA Has Received Paragraph IV Notice Letter for Kuvan(R),2014-09-24 17:22:00-04:00,BMRN,neutral
174694.0,From BioMarin 8-K: Lowers FY2014 Sales Guidance from $745.0M-765.0M to $680.0M-700.0M vs $768.70M Est,2014-08-26 16:25:00-04:00,BMRN,negative
174695.0,BioMarin Weathers The Storm,2014-08-06 16:02:00-04:00,BMRN,neutral
174696.0,Biomarin Pharma Shares Spike to High on Volume,2014-07-31 11:04:00-04:00,BMRN,positive
174697.0,BioMarin Pharmaceutical Inc. Reports Q2 EPS of $(0.23) Which May Not Compare $(0.41) Est; Revenue of $191.80M Which May Not Compare $159.69M Est,2014-07-30 16:02:00-04:00,BMRN,neutral
174698.0,BioMarin Announces Health Canada Approval of VIMIZIM for Treatment of Morquio A Syndrome,2014-07-07 08:01:00-04:00,BMRN,positive
174699.0,"UBS Initiates Coverage on BioMarin Pharmaceutical Inc. at Buy, Announces $74.00 PT",2014-06-11 16:33:00-04:00,BMRN,neutral
174700.0,UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical,2014-06-09 09:41:00-04:00,BMRN,positive
174701.0,Benzinga's Top Upgrades,2014-06-09 07:52:00-04:00,BMRN,positive
174702.0,"Credit Suisse Upgrades BioMarin Pharmaceutical Inc. to Outperform, Maintains $73.00 PT",2014-06-09 06:46:00-04:00,BMRN,positive
174703.0,Credit Suisse Upgrades BioMarin Pharmaceutical Inc. to Outperform,2014-06-09 06:21:00-04:00,BMRN,positive
174704.0,"Option Alert: Biomarin Pharmaceutical Jun $70 Call; 2,620 Contract Trade at Ask @$0.50; OI 449; Currently $61.46",2014-06-03 15:31:00-04:00,BMRN,positive
174705.0,"Nomura Maintains Neutral on BioMarin Pharmaceutical Inc., Lowers PT to $77.00",2014-05-02 07:49:00-04:00,BMRN,negative
174706.0,BioMarin Pharmaceutical Inc. Reports Q1 EPS of $(0.01) vs $(0.46) Est; Revenue of $151.60M vs $145.51M Est,2014-05-01 16:49:00-04:00,BMRN,neutral
174707.0,BioMarin Pharmaceutical Inc. Reports Q1 EPS of $(0.27) vs $(0.46) Est; Revenue of $151.60M vs $145.51M Est,2014-05-01 16:09:00-04:00,BMRN,neutral
174708.0,BioMarin Shares Move Lower Despite Release Highlighting EC Approval/Orphan Drug Status for VIMIZIM for Treatment of Morquio A Syndrome,2014-04-28 11:14:00-04:00,BMRN,neutral
174709.0,FDA Extends Market Exclusivity Six Months for BioMarin's KUVAN,2014-04-14 08:44:00-04:00,BMRN,positive
174710.0,Shares of BioMarin Down ~3.4% Over Last 10 Mins,2014-03-25 12:24:00-04:00,BMRN,positive
174711.0,UPDATE: News of BioMarin Appointment of Slamon as Director Was Issued in Press Release on Mar 21st,2014-03-25 12:21:00-04:00,BMRN,neutral
174712.0,Form 8-K from BioMarin Shows Appointment of Dennis Slamon to Board,2014-03-25 12:21:00-04:00,BMRN,neutral
174713.0,"Goldman Sachs Downgrades BioMarin Pharmaceutical Inc. to Neutral, Maintains $84.00 PT",2014-03-25 08:08:00-04:00,BMRN,neutral
174714.0,"BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, BMRN, MDVN)",2014-03-12 10:01:00-04:00,BMRN,positive
174715.0,BioMarin Prices 1.5M Share Offering of Common Stock ,2014-03-05 08:15:00-05:00,BMRN,positive
174716.0,BioMarin Announces Offering of 1.5M Shares of Common Stock,2014-03-04 16:22:00-05:00,BMRN,positive
174717.0,Biotechs vs. Pharmaceuticals: What's the Difference?,2014-03-04 10:30:00-05:00,BMRN,neutral
174718.0,"Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, BMRN)",2014-02-27 12:26:00-05:00,BMRN,positive
174719.0,"Nomura Maintains Neutral on BioMarin Pharmaceutical Inc., Raises PT to $86.00",2014-02-27 08:08:00-05:00,BMRN,neutral
174720.0,BioMarin Pharmaceutical Inc. Reports Q4 EPS of $(0.44) vs $(0.35) Est; Revenue of $146.90M vs $146.07M Est,2014-02-26 16:06:00-05:00,BMRN,neutral
174721.0,EMA Isuses New Compassionate-Use Programme,2014-02-21 08:09:00-05:00,BMRN,neutral
174722.0,BioMarin Receives Position Opinion from CHMP for Vimizim,2014-02-20 11:23:00-05:00,BMRN,neutral
174723.0,Top Trending Tickers On StockTwits For February 18,2014-02-18 10:22:00-05:00,BMRN,positive
174724.0,"BioMarin Pharmaceutical Inc. Sees FY2014 Sales $650.0M-680.0M, Sees Non-GAAP Loss in $100M-130M Range",2014-02-18 08:35:00-05:00,BMRN,negative
174725.0,BioMarin Confirms FDA Approval for VIMIZIM,2014-02-14 16:32:00-05:00,BMRN,positive
174726.0,FDA Approves Vimizim to Treat Rare Congenital Enzyme Disorder,2014-02-14 15:21:00-05:00,BMRN,positive
174727.0,"BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)",2014-02-13 10:18:00-05:00,BMRN,positive
174728.0,BioMarin Announces Selection of NAGLU Fusion Protein Drug Development,2014-02-11 08:01:00-05:00,BMRN,neutral
174729.0,"New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)",2014-01-29 11:44:00-05:00,BMRN,positive
174730.0,"BioMarin Confirms Deal with Repligen for HDACI Portfolio, Will Pay $2M Upfront",2014-01-21 07:37:00-05:00,BMRN,negative
174731.0,"Repligen Announces Asset Buy Deal with BioMarin for HDACI Portfolio, Will Receive Upfront Payment of $2M, Has Potential for Added Milestones of Up to $160M",2014-01-21 07:32:00-05:00,BMRN,positive
174732.0,"BioMarin Announces Selection of Factor VIII Gene Therapy Drug Development, Sees Initiating Clinical Study with BMN 270 in Early 2015",2014-01-13 08:09:00-05:00,BMRN,neutral
174733.0,"Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, CELG, DNDN)",2014-01-11 11:46:00-05:00,BMRN,positive
174734.0,Catalyst Pharma Says Study of Cardiac Safety in Phase 3 Trial of Firdapse Met Primary Endpoint,2014-01-08 08:04:00-05:00,BMRN,positive
174735.0,"Nomura Initiates Coverage on BioMarin Pharmaceutical Inc. at Neutral, Announces $75.00 PT",2014-01-08 07:48:00-05:00,BMRN,neutral
174736.0,"Catalyst Pharma Reports Successful Completion of Type B FDA Meeting, Will Submit Data from Added In-Vitro Preclinical Trial",2014-01-06 08:05:00-05:00,BMRN,positive
174737.0,"Form 8-K from Biomarin Pharma Shows Pact to Buy San Rafael Corp. Center for $116.5M, Deposited $10M",2013-12-23 14:30:00-05:00,BMRN,neutral
174738.0,"Option Alert: Biomarin December $70/Janaury $75 Call Spread; 2,000 Spread Contract Trade; Currently $70.00",2013-12-05 11:53:00-05:00,BMRN,positive
174739.0,BioMarin Submits VIMIZIM NDS to Health Canada for Treatment of Morquio A Syndrome Under Priority Review Status,2013-12-04 08:03:00-05:00,BMRN,neutral
174740.0,UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical on Expected Attractive Returns,2013-11-27 11:10:00-05:00,BMRN,positive
174741.0,UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On BMN-111 Outlook,2013-11-27 07:50:00-05:00,BMRN,neutral
174742.0,Piper Jaffray Reinstates Overweight on BioMarin Pharmaceutical Inc.,2013-11-26 16:23:00-05:00,BMRN,negative
174743.0,"Option Alert: Biomarin December $80 Call; 2,500 Contract Trade at Ask @$0.65; Currently $70.71",2013-11-21 09:52:00-05:00,BMRN,positive
174744.0,Benzinga's Top #PreMarket Gainers,2013-11-20 08:26:00-05:00,BMRN,positive
174745.0,Myriad Genetics Says Received Second HRD Pact with BioMarin,2013-11-20 07:05:00-05:00,BMRN,neutral
174746.0,Shares of BioMarin Now Up 5+%,2013-11-19 17:43:00-05:00,BMRN,positive
174747.0,"BioMarin Shares Resume Trading, Now Up Just 0.66%",2013-11-19 17:30:00-05:00,BMRN,positive
174748.0,Shares of BioMarin to Resume Trading at 5:30PM EST,2013-11-19 17:21:00-05:00,BMRN,positive
174749.0,BioMarin Confirms FDA Panel Recommends Approval of Vimizim for Treatment of Patients with Morquio A Syndrome,2013-11-19 17:04:00-05:00,BMRN,positive
174750.0,FDA Panel Votes BioMarin's Vimizim Should Be Approved,2013-11-19 16:04:00-05:00,BMRN,positive
174751.0,FDA Panel Votes 16-5 BioMarin's NDA for Vimizim Does Not Raise Safety Concerns,2013-11-19 15:56:00-05:00,BMRN,negative
174752.0,FDA Advisory Committee Says BioMarin's Data Shows Vimizim Works for Rare Disease,2013-11-19 15:41:00-05:00,BMRN,neutral
174753.0,BioMarin Stock Trading Halted Today for FDA Endocrinologic and Metabolic Drugs Advisory Committee,2013-11-19 07:11:00-05:00,BMRN,neutral
174754.0,BioMarin Says Stock Halted Ahead of FDA Advisory Committee for Review of Vimizim Application,2013-11-19 07:11:00-05:00,BMRN,neutral
174755.0,BioMarin Reports French ATU Granted for Vimizim for the Treatment of Morquio,2013-11-15 08:06:00-05:00,BMRN,positive
174756.0,Gilead Sciences Leads In Rising Short Interest Among Biotechs ,2013-11-12 16:41:00-05:00,BMRN,positive
174757.0,BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA Breast Cancer ,2013-10-31 05:58:00-04:00,BMRN,negative
174758.0,"Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)",2013-10-25 15:36:00-04:00,BMRN,positive
174759.0,BioMarin Pharmaceutical Inc. Reports Q3 EPS of $(0.38) vs $(0.30) Est,2013-10-24 17:01:00-04:00,BMRN,neutral
174760.0,"US Oncology, Biomarin Announce Collaboration to Launch PARP Inhibitor Phase III Study in BRCA Metastatic Breast Cancer Patients",2013-10-24 10:05:00-04:00,BMRN,negative
174761.0,BioMarin Announces 5 Poster Presentations on BMN 673 at AACR-NCI-EORTC International Conference ,2013-10-20 17:01:00-04:00,BMRN,neutral
174762.0,"Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)",2013-10-11 14:33:00-04:00,BMRN,neutral
174763.0,BioMarin Files Automatic Mixed Securities Shelf,2013-10-07 16:30:00-04:00,BMRN,positive
174764.0,BioMarin Presents Positive Phase 1/2 Data on BMN 673 in Breast Cancer at ECC 2013,2013-09-29 10:46:00-04:00,BMRN,negative
174765.0,"BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)",2013-09-25 12:52:00-04:00,BMRN,positive
174766.0,BioMarin Reports First Patient in Phase 1/2 Trial for BMN 190 for Treatment of NCL Type 2,2013-09-23 09:01:00-04:00,BMRN,neutral
174767.0,"Market Primer: Friday, September 20: US Markets Fall As Investors Re-Evaluate",2013-09-20 06:45:00-04:00,BMRN,neutral
174768.0,"Benzinga's M&A Chatter for Thursday September 19, 2013",2013-09-19 17:47:00-04:00,BMRN,neutral
174769.0,"BioMarin Shares Hanging Onto Gains Despite Comment from Roche CEO Co. Not Raising Financing, Note from Wells Fargo Saying BioMarin Not a Clean Fit for Roche",2013-09-19 12:20:00-04:00,BMRN,positive
174770.0,Benzinga's Volume Movers,2013-09-19 10:52:00-04:00,BMRN,neutral
174771.0,Biomarin Shares Pullback on Roche CEO Comments that Company is Not Raising Financing,2013-09-19 08:50:00-04:00,BMRN,positive
174772.0,Benzinga's Top Pre-Market Gainers,2013-09-19 08:09:00-04:00,BMRN,positive
174773.0,Roche Declines Comment on Rumored Bid for Biomarin Pharmaceutical,2013-09-19 07:30:00-04:00,BMRN,neutral
174774.0,UPDATE: Biomarin Shares Rise 8% on Report Roche May Bid Up to $105/Share,2013-09-19 06:52:00-04:00,BMRN,positive
174775.0,Hearing Deal Reporter Says Roche May Acquire Biomarin for $95-$105/Share,2013-09-19 06:20:00-04:00,BMRN,neutral
174776.0,"UPDATE: Stifel Downgrades BioMarin Pharmaceutical on Appropriate Risk/Reward, Expected Slower Data Flow",2013-09-18 10:27:00-04:00,BMRN,neutral
174777.0,Benzinga's Top Pre-Market Gainers,2013-09-18 08:08:00-04:00,BMRN,positive
174778.0,"Jefferies Maintains Buy on BioMarin Pharmaceutical Inc., Raises PT to $86.00",2013-09-18 07:53:00-04:00,BMRN,neutral
174779.0,"Stifel Nicolaus Downgrades BioMarin Pharmaceutical Inc. to Hold, Removes $70.00 PT",2013-09-18 07:46:00-04:00,BMRN,neutral
174780.0,Biomarin CEO Bienaim: 'Our New Drug Should Double Our Revenue in the Next Few Years',2013-09-17 18:47:00-04:00,BMRN,neutral
174781.0,Biomarin CEO Bienaim: 'Most of Our Drugs are for Ultra Orphan DIsorders',2013-09-17 18:45:00-04:00,BMRN,neutral
174782.0,Biomarin Pharmaceutical Shares Move Higher Ahead of Jim Cramer Interview with CEO Jean-Jacques Bienaim ,2013-09-17 18:44:00-04:00,BMRN,positive
174783.0,"Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)",2013-09-14 11:47:00-04:00,BMRN,positive
174784.0,"Canaccord Genuity Maintains Buy on BioMarin Pharmaceutical Inc., Raises PT to $85.00",2013-09-05 10:07:00-04:00,BMRN,neutral
174785.0,"Stocks to Watch for July 29, 2013",2013-07-29 13:41:00-04:00,BMRN,neutral
174786.0,Biomarin Pharma Expecting FY Net Loss $160-185M vs Prior Guidance for Loss of $170-195M ,2013-07-25 16:22:00-04:00,BMRN,negative
174787.0,BioMarin Pharmaceutical Inc. Reports Q2 EPS of $(0.16) vs $(0.29) Est; Revenue of $136.81M vs $134.33M Est,2013-07-25 16:22:00-04:00,BMRN,neutral
174788.0,BioMarin Provides BMN 673 Program Update ,2013-07-25 16:05:00-04:00,BMRN,neutral
174789.0,BioMarin Announces Marketing Application for Vimizim Submitted to Brazilian Regulators,2013-07-01 09:03:00-04:00,BMRN,neutral
174790.0,A Peek Into The Market Before The Trading Starts,2013-06-05 07:08:00-04:00,BMRN,neutral
174791.0,BioMarin Announces Initiation of Phase 3 PEG-PAL Trial for PKU ,2013-06-05 06:10:00-04:00,BMRN,neutral
174792.0,UPDATE: Deutsche Bank Upgrades BioMarin to Buy on Weak Stock Opportunity ,2013-06-04 08:33:00-04:00,BMRN,neutral
174793.0,"BioMarin CEO Bienaim: 'AstraZeneca is a Significant Competitor, But we are 1000 Times more Potent than the Company'",2013-06-03 18:50:00-04:00,BMRN,positive
174794.0,BioMarin CEO Bienaim: 'Our Product is One Tablet/Day',2013-06-03 18:48:00-04:00,BMRN,neutral
174795.0,"BioMarin CEO Bienaim: 'Ovarian Results were Pretty Astonishing, Breast Results were also Good'",2013-06-03 18:47:00-04:00,BMRN,positive
174796.0,Jim Cramer Interviews CEO Jean-Jacques Bienaim of BioMarin Pharmaceutical on Mad Money,2013-06-03 18:45:00-04:00,BMRN,negative
174797.0,"Deutsche Bank Upgrades BioMarin Pharmaceutical Inc. to Buy, Maintains $75.00 PT",2013-06-03 15:39:00-04:00,BMRN,neutral
174798.0,UPDATE: Leerink Reiterates Outperform on BioMarin on Positive Cancer Drug Test Results,2013-06-03 13:13:00-04:00,BMRN,negative
174799.0,"Mid-Day Market Update: Markets Turn Mixed, Colonial Properties Gains On Acquisition News",2013-06-03 12:27:00-04:00,BMRN,positive
174800.0,"Mid-Morning Market Update: Markets Rise, Cracker Barrel Posts Upbeat Earnings",2013-06-03 10:34:00-04:00,BMRN,neutral
174801.0,"BioMarin Shares Remain at Lows Despite Piper Jaffray Note Defending News of Clovis, Tesaro Data Updates at ASCO, Says BioMarin's BMN-673 'Looks Competitive;' Reiterates Overweight, $70 Target",2013-06-03 10:33:00-04:00,BMRN,negative
174802.0,Hearing Piper Defending Biomarin,2013-06-03 10:29:00-04:00,BMRN,neutral
174803.0,BioMarin Provides Preliminary Data on Ongoing Phase 1/2 Trial for BMN 673 for the Treatment of Solid Tumors at 2013 American Society of Clinical Oncology Annual Meeting,2013-06-03 09:02:00-04:00,BMRN,positive
174804.0,UPDATE: Credit Suisse Initiates BioMarin Pharmaceutical at Neutral on Revenue Growth Forecast,2013-05-31 10:06:00-04:00,BMRN,positive
174805.0,"Credit Suisse Initiates Coverage on BioMarin Pharmaceutical Inc. at Neutral, Announces $68.00 PT",2013-05-31 08:24:00-04:00,BMRN,positive
174806.0,"Biomarin Announces FDA Acceptance of  Vimizim BLA, Receives Priority Review Designation ",2013-05-30 07:08:00-04:00,BMRN,positive
174807.0,Biomarin's Vimizim MAA Validated by the EMA ,2013-05-30 07:02:00-04:00,BMRN,positive
174808.0,"Goldman Sachs Initiates Coverage on BioMarin Pharmaceutical Inc. at Buy, Announces $80.00 PT",2013-05-07 06:44:00-04:00,BMRN,neutral
174809.0,BioMarin Pharmaceutical Inc. Reports Q1 EPS of $(0.31) vs $(0.30) Est; Revenue of $127.90M vs $131.45M Est,2013-04-25 16:09:00-04:00,BMRN,neutral
174810.0,BioMarin Submits CTA for BMN-190 for Batten Disease,2013-04-01 09:03:00-04:00,BMRN,neutral
174811.0,Biomarin Closes Added Partial Exchange of Convertible Notes Due 2017,2013-03-25 09:01:00-04:00,BMRN,neutral
174812.0,UPDATE: Jefferies Raises PT on BioMarin Pharmaceutical as BMN-701 Moves Forward,2013-03-20 11:49:00-04:00,BMRN,neutral
174813.0,UPDATE: Wedbush Raises PT on BioMarin Pharmaceuticals on Positive Phase 2 Data,2013-03-20 10:41:00-04:00,BMRN,positive
174814.0,UPDATE: Piper Jaffray Raises PT on BioMarin Pharmaceutical on Positive Trial Results,2013-03-20 09:26:00-04:00,BMRN,positive
174815.0,UPDATE: Deutsche Bank Raises PT on BioMarin Pharmaceuticals on Pipeline Outlook,2013-03-20 08:17:00-04:00,BMRN,neutral
174816.0,"Piper Jaffray Maintains Overweight on BioMarin Pharmaceutical Inc., Raises PT to $70.00",2013-03-20 07:30:00-04:00,BMRN,negative
174817.0,"Deutsche Bank Maintains Hold on BioMarin Pharmaceutical Inc., Raises PT to $59.00",2013-03-20 06:44:00-04:00,BMRN,neutral
174818.0,"BioMarin to Advance BMN-701 for Pompe Disease to Next Phase of Trials, Sees Phase 2/3 Switching Trial by End of 2013",2013-03-19 16:22:00-04:00,BMRN,neutral
174819.0,BioMarin Pharmaceutical Inc. Sees FY2013 Sales $530.0M-555.0M vs $555.70M Est,2013-02-21 16:36:00-05:00,BMRN,neutral
174820.0,BioMarin Pharmaceutical Inc. Reports Q4 EPS of $(0.43) vs $(0.27) Est; Revenue of $131.94M vs $129.74M Est,2013-02-21 16:36:00-05:00,BMRN,neutral
174821.0,"Piper Jaffray Maintains Overweight on BioMarin Pharmaceutical Inc., Raises PT to $64.00",2013-02-19 14:14:00-05:00,BMRN,negative
174822.0,BioMarin Reports Statistically Significant Changes in Kuvan Responding PKU Patients,2013-02-19 09:05:00-05:00,BMRN,positive
174823.0,"Jefferies Maintains Buy on BioMarin Pharmaceutical Inc., Raises PT to $65.00",2013-02-19 08:33:00-05:00,BMRN,neutral
174824.0,UPDATE: Canaccord Genuity Raises PT to $71 on BioMarin Pharmaceutical on Upcoming Catalysts,2013-02-12 13:22:00-05:00,BMRN,neutral
174825.0,"Canaccord Genuity Maintains Buy on BioMarin Pharmaceutical Inc., Raises PT to $71.00",2013-02-12 08:04:00-05:00,BMRN,neutral
174826.0,"UBS Maintains Buy on BioMarin Pharmaceutical Inc., Raises PT to $67.00",2013-02-01 10:00:00-05:00,BMRN,neutral
174827.0,"Wunderlich Suspends Hold Rating on BioMarin Pharmaceutical Inc., Removes $40.00 PT",2013-01-25 16:12:00-05:00,BMRN,neutral
174828.0,UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts,2013-01-22 13:47:00-05:00,BMRN,neutral
174829.0,"Stifel Nicolaus Upgrades BioMarin Pharmaceutical Inc. to Buy, Announces $67.00 PT",2013-01-22 08:31:00-05:00,BMRN,neutral
174830.0,Stifel Nicolaus Upgrades BioMarin Pharmaceutical Inc. to Buy,2013-01-22 08:27:00-05:00,BMRN,neutral
174831.0,"Reuters Reporting BioMarin CEO Said Co. Won't Sell Itself, Even for 25-30% Premium",2013-01-08 14:24:00-05:00,BMRN,neutral
174832.0,BioMarin Buys Zacharon Pharma for $10M,2013-01-07 09:08:00-05:00,BMRN,neutral
174833.0,"Janney Capital Initiates Coverage on BioMarin Pharmaceutical Inc. at Buy, Announces $60.00 PT",2013-01-02 17:06:00-05:00,BMRN,neutral
174834.0,"J.P. Morgan Reiterates Overweight Rating, $60 PT on BioMarin Pharmaceutical",2013-01-02 14:14:00-05:00,BMRN,negative
174835.0,UPDATE: Wedbush Reiterates BioMarin Pharmaceuticals at Neutral with $46 PT  ,2012-12-07 12:46:00-05:00,BMRN,neutral
174836.0,"BioMarin, Prestige Brands and Other Top Performing Health Care Stocks in November",2012-12-02 20:29:00-05:00,BMRN,positive
174837.0,BioMarin Halted on Circuit Breaker,2012-11-15 09:51:00-05:00,BMRN,neutral
174838.0,"Barclays Maintains BioMarin Pharmaceuticals at Overweight, Raises PT from $46 to $54",2012-11-06 13:49:00-05:00,BMRN,negative
174839.0,Brean Murray Downgraded BioMarin Pharmaceuticals from Buy to Hold,2012-11-06 09:54:00-05:00,BMRN,neutral
174840.0,"Wedbush Securities Maintains BioMarin Pharmaceuticals at Neutral, Raises PT from $41 to $46",2012-11-05 15:45:00-05:00,BMRN,positive
174841.0,"Mid-Afternoon Market Update: Markets Rally, Vringo Jumps",2012-11-05 15:31:00-05:00,BMRN,neutral
174842.0,UPDATE: Canaccord Genuity Raises PT to $56 on BioMarin Pharmaceutical on Value Inflection Outlook  ,2012-11-05 14:02:00-05:00,BMRN,positive
174843.0,"Citigroup Maintains BioMarin Pharmaceuticals at Buy, Raises PT from $47 to $61",2012-11-05 13:13:00-05:00,BMRN,neutral
174844.0,"Canaccord Maintains BioMarin Pharmaceuticals at Buy, Raises PT from $52 to $56",2012-11-05 13:12:00-05:00,BMRN,neutral
174845.0,"Jefferies & Company Maintains BioMarin Pharmaceuticals at Buy, Raises PT from $46 to $60",2012-11-05 13:12:00-05:00,BMRN,neutral
174846.0,"Mid Morning Market Update: Markets Decline, Stifel Financial Acquires KBW",2012-11-05 10:28:00-05:00,BMRN,neutral
174847.0,Stocks Hitting 52-Week Highs,2012-11-05 10:07:00-05:00,BMRN,neutral
174848.0,BioMarin Phase 3 Study of GALNS  Meets Primary Endpoint ,2012-11-05 07:19:00-05:00,BMRN,neutral
174849.0,BioMarin Pharmaceuticals Reports Q3 EPS $-0.04 vs $-0.20 Est; Revenues $128.12M vs $127.38M Est,2012-10-25 16:53:00-04:00,BMRN,neutral
174850.0,UPDATE: Jefferies Raises PT to $46 on BioMarin Pharmaceutical Ahead of GALNS Data  ,2012-10-03 12:39:00-04:00,BMRN,neutral
174851.0,"Jefferies & Company Maintains BioMarin Pharmaceuticals at Buy, Raises PT from $44 to $46",2012-10-03 06:15:00-04:00,BMRN,neutral
174852.0,"JP Morgan Maintains BioMarin Pharmaceuticals at Overweight, Raises PT from $47 to $50",2012-09-27 06:47:00-04:00,BMRN,neutral
174853.0,"Wedbush Securities Maintains BioMarin Pharmaceuticals at Neutral, Raises PT from $37 to $39",2012-09-27 06:46:00-04:00,BMRN,positive
174854.0,"BioMarin Announces Decision to Start Phase 3 Program for PEG-PAL; Says Phase 2 Meeting with FDA in Q1, Drug Generally Well-Tolerated in Phase 2",2012-09-26 16:02:00-04:00,BMRN,neutral
174855.0,William Blair   on BioMarin Pharmaceuticals,2012-09-12 06:45:00-04:00,BMRN,neutral
174856.0,"Biomarin Speaking at Conference, Guides FY12 Revenue About $500M vs $496.36M Est",2012-09-07 10:38:00-04:00,BMRN,neutral
174857.0,Deutsche Bank Downgrades BioMarin From Buy to Hold,2012-08-27 10:12:00-04:00,BMRN,neutral
174858.0,Benzinga's Top Downgrades,2012-08-27 07:32:00-04:00,BMRN,positive
174859.0,UPDATE: Deutsche Bank Downgrades BioMarin Pharmaceuticals to Hold on GALNS Risk/Reward  ,2012-08-27 06:56:00-04:00,BMRN,neutral
174860.0,"Deutsche Bank Downgrades BioMarin Pharmaceuticals from Buy to Hold, Announces PT of $45",2012-08-27 05:54:00-04:00,BMRN,neutral
174861.0,"Barclays Initiates Coverage on BioMarin Pharmaceuticals at Overweight, Announces PT of $46",2012-08-24 10:13:00-04:00,BMRN,negative
174862.0,"Jefferies & Company Maintains BioMarin Pharmaceuticals at Buy, Raises PT from $40 to $44",2012-08-02 06:29:00-04:00,BMRN,neutral
174863.0,BioMarin Pharmaceuticals Reports Q2 EPS $-0.27 vs $-0.21 Est; Revenues $124M vs $121.69M Est,2012-08-01 16:34:00-04:00,BMRN,neutral
174864.0,BioMarin Pharmaceutical Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)  ,2012-07-25 09:09:00-04:00,BMRN,positive
174865.0,"Morgan Stanley Maintains BioMarin Pharmaceuticals at Buy, Raises PT from $43 to $52",2012-07-23 06:16:00-04:00,BMRN,neutral
174866.0,"Option Alert: BioMarin Pharmaceutical August 55 Call; Block Trade: 2,500 Contracts @$0.60, Currently $43.47",2012-07-13 14:49:00-04:00,BMRN,negative
174867.0,Biomarin Pharmaceutical Spiking Lower,2012-07-11 13:45:00-04:00,BMRN,negative
174868.0,"Option Alert: BioMarin Pharmaceutical August 45 Call; Block Trade: 10,076 Contracts @$1.90, Currently $42.17",2012-07-10 14:44:00-04:00,BMRN,negative
174869.0,"Dendreon, Pharmacyclics and Other Biotech Takeover Targets",2012-07-10 14:07:00-04:00,BMRN,neutral
174870.0,BioMarin Pharmaceutical Hits New 52-Week High on Continued Takeover Chatter,2012-06-29 12:03:00-04:00,BMRN,neutral
174871.0,ThinkEquity Initiates Coverage on BioMarin Pharmaceuticals at Buy,2012-06-29 06:53:00-04:00,BMRN,neutral
174872.0,"Benzinga's M&A Chatter for Thursday June 28, 2012",2012-06-28 18:20:00-04:00,BMRN,neutral
174873.0,Spokesperson for BioMarin Pharmaceutical Won't Comment on Guardian Report on Takeover Bids,2012-06-28 13:45:00-04:00,BMRN,neutral
174874.0,Editor of Little Bear Blog is Long BioMarin Pharmaceutical on Takeover Chatter,2012-06-28 12:26:00-04:00,BMRN,neutral
174875.0,"UPDATE: BioMarin Spikes Higher on Report GlaxoSmithKline, Sanofi, Biogen Could Bid $60/Share -Guardian",2012-06-28 12:10:00-04:00,BMRN,neutral
174876.0,Biomarin Spikes Higher on Takeover Chatter,2012-06-28 12:08:00-04:00,BMRN,neutral
174877.0,BioMarin CEO Bienaim: 'We Look at a Significant Improvement in a Small Patient Population',2012-06-19 18:21:00-04:00,BMRN,positive
174878.0,BioMarin CEO Bienaim: 'All the Patients We Serve Are Extremely Sick With Life Threatening Diseases',2012-06-19 18:20:00-04:00,BMRN,negative
174879.0,Jim Cramer Interviews CEO Jean-Jacques Bienaim of BioMarin Pharmaceutical on Mad Money,2012-06-19 18:17:00-04:00,BMRN,negative
174880.0,"Benzinga's M&A Chatter for Tuesday June 19, 2012",2012-06-19 17:21:00-04:00,BMRN,neutral
174881.0,BioMarin Pharmaceutical Spokesperson Won't Comment on dealReporter Story Regarding Prospects of Sale of the Company,2012-06-19 14:41:00-04:00,BMRN,positive
174882.0,Hearing Negative dealReporter Article on Biomarin Pharmaceutical ,2012-06-19 14:21:00-04:00,BMRN,negative
174883.0,"BioMarin Pharmaceutical Reiterates 2012 Revenue Outlook $475M to $510M, vs Consensus $494.9M  ",2012-06-14 10:12:00-04:00,BMRN,neutral
174884.0,BioMarin Pharmaceutical Says Have Sales in 45 Countries,2012-06-14 10:03:00-04:00,BMRN,neutral
174885.0,BioMarin Pharmaceutical Says Revenue Stream is Growing,2012-06-14 10:03:00-04:00,BMRN,positive
174886.0,BioMarin Pharmaceutical Says Revenues over Next 2 Years Going into R&D,2012-06-14 10:00:00-04:00,BMRN,neutral
174887.0,BioMarin Pharmaceutical Commenting on Batten Disease Study,2012-06-14 09:59:00-04:00,BMRN,neutral
174888.0,BioMarin Pharmaceutical Presents at William Blair Growth Stock Conference,2012-06-14 09:40:00-04:00,BMRN,positive
174889.0,"Benzinga's M&A Chatter for Tuesday June 12, 2012",2012-06-12 17:32:00-04:00,BMRN,neutral
174890.0,Spokesperson for BioMarin Pharmaceutical Won't Comment on Earlier Takeover Chatter,2012-06-12 15:09:00-04:00,BMRN,neutral
174891.0,Benzinga's Top Pre-Market Gainers,2012-06-12 08:06:00-04:00,BMRN,positive
174892.0,"From Earlier: Wedbush Reiterates BioMarin Pharmaceuticals Neutral, FV To $35",2012-06-08 16:49:00-04:00,BMRN,neutral
174893.0,"Benzinga's Morning Initiation Summary for June 1, 2012",2012-06-01 10:55:00-04:00,BMRN,neutral
174894.0,BioMarin Pharmaceutical Falls 4% Pre-Market on Offering of 6.5M Shares,2012-05-31 08:49:00-04:00,BMRN,positive
174895.0,BioMarin Announces Pricing of Public Offering of Common Stock; 6.5M Shares for $248.885M,2012-05-31 08:47:00-04:00,BMRN,positive
174896.0,BioMarin Pharma Files Common Stock Shelf Registration,2012-05-30 16:41:00-04:00,BMRN,neutral
174897.0,BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ,2012-05-30 09:03:00-04:00,BMRN,positive
174898.0,Top 10 Small Cap ETFs,2012-05-15 14:48:00-04:00,BMRN,positive
174899.0,UPDATE: Citi Raises BioMarin Pharmaceuticals' PT,2012-05-14 08:46:00-04:00,BMRN,neutral
174900.0,"Citigroup Maintains BioMarin Pharmaceuticals at Buy, Raises PT from $45 to $49",2012-05-14 07:03:00-04:00,BMRN,neutral
174901.0,BioMarin Appoints Dan Spiegelman as Executive Vice President and Chief Financial Officer  ,2012-05-08 16:05:00-04:00,BMRN,neutral
174902.0,BioMarin Pharmaceuticals Reports Q1 EPS $-0.21 vs $-0.14 Est; Revenues $116.6M vs $118.78M Est,2012-04-26 16:49:00-04:00,BMRN,neutral
174903.0,"UBS Initiates Coverage on BioMarin Pharmaceuticals at Buy, Announces PT of $43",2012-04-12 12:22:00-04:00,BMRN,neutral
174904.0,"Canaccord Initiates Coverage on BioMarin Pharmaceuticals at Buy, Announces PT of $43",2012-03-26 08:55:00-04:00,BMRN,neutral
174905.0,UPDATE: Brean Murray Carret Upgrades BioMarin Pharmaceutical to Buy,2012-03-19 12:12:00-04:00,BMRN,neutral
174906.0,Benzinga's Top Upgrades,2012-03-19 07:25:00-04:00,BMRN,positive
174907.0,"Brean Murray Carret & Co. Upgrades BioMarin Pharmaceuticals from Hold to Buy, Maintains PT at $41",2012-03-19 06:26:00-04:00,BMRN,neutral
174908.0,BioMarin Completes Enrollment for Phase 3 Trial for GALNS for the Treatment of MPS IVA,2012-03-08 09:02:00-05:00,BMRN,neutral
174909.0,BioMarin Announces Chief Financial Officer Jeffrey Cooper to Leave the Company ,2012-02-21 09:01:00-05:00,BMRN,negative
174910.0,BioMarin Guides $255-265M for R&D in 2012,2012-02-16 17:13:00-05:00,BMRN,neutral
174911.0,BioMarin Pharmaceuticals Reports Q4 EPS $(0.23) vs $(0.11) Est; Revenues $107.85M vs $115.30M Est		 ,2012-02-16 16:05:00-05:00,BMRN,neutral
174912.0,BioMarin Initiates Phase 1 Trial for BMN-111 for the Treatment of Achondroplasia,2012-02-16 16:00:00-05:00,BMRN,neutral
174913.0,BioMarin Pharmaceutical CEO: Expect 2012 Revenues to be Greater than 2011 -CNBC,2012-02-14 14:26:00-05:00,BMRN,positive
174914.0,BioMarin Pharmaceuticals Hits 52-Week High of $38.66,2012-02-13 09:49:00-05:00,BMRN,neutral
174915.0,BioMarin Pharmaceuticals Hits 52-Week High of $38.22,2012-02-06 11:32:00-05:00,BMRN,neutral
174916.0,BioMarin Pharmaceuticals Hits 52-Week High of $38.13,2012-02-03 09:47:00-05:00,BMRN,neutral
174917.0,BioMarin Pharmaceuticals Hits 52-Week High of $37.85,2012-02-02 10:01:00-05:00,BMRN,neutral
174918.0,Just What The Doctor Ordered: 4 ETFs For Biotech M&A,2012-01-09 15:49:00-05:00,BMRN,neutral
174919.0,JPMorgan Confab Kicks Off Biotech 2012,2012-01-05 11:46:00-05:00,BMRN,neutral
174920.0,BioMarin Receives Positive Opinion from European Regulatory Authorities for Expanded Biologics Manufacturing Facility,2011-12-19 09:02:00-05:00,BMRN,positive
174921.0,Stifel Nicolaus Maintains Hold on BioMarin Pharmaceuticals,2011-12-09 09:29:00-05:00,BMRN,neutral
174922.0,Brean Murray Maintains Hold on BioMarin Pharma After Analyst Day,2011-12-09 09:28:00-05:00,BMRN,neutral
174923.0,BioMarin Announces Buy Back of Naglazyme Royalties From Adelaide Health Authority for $81M,2011-11-30 16:00:00-05:00,BMRN,positive
174924.0,"Wedbush Maintains Neutral, $34 Target on BioMarin Pharmaceuticals ",2011-11-30 08:21:00-05:00,BMRN,neutral
174925.0,BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA ,2011-11-29 16:00:00-05:00,BMRN,neutral
174926.0,BioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility ,2011-11-28 09:01:00-05:00,BMRN,positive
174927.0,"BioMarin Pharmaceutical Hits New 52-Week High, $34.85",2011-10-28 09:58:00-04:00,BMRN,neutral
174928.0,UPDATE: J.P. Morgan Raises PT on BioMarin Pharmaceuticals to $38,2011-10-28 09:08:00-04:00,BMRN,neutral
174929.0,"JP Morgan Raises PT on BioMarin Pharmaceuticals from $35 to $38, Maintains Overweight",2011-10-28 07:24:00-04:00,BMRN,neutral
174930.0,BioMarin Pharmaceutical Reports Q3 EPS $(0.16) vs $(0.10) Est; Revenues $113.43M vs $113.28M Est	,2011-10-27 16:24:00-04:00,BMRN,neutral
174931.0,UPDATE: Jefferies Raises PT on BioMarin Pharma to $38,2011-10-17 10:00:00-04:00,BMRN,neutral
174932.0,Jefferies Raises PT on BioMarin Pharmaceuticals to $38,2011-10-17 07:31:00-04:00,BMRN,neutral
174933.0,Piper Jaffray Overweight on BioMarin Pharmaceutical  (BMRN,2011-10-03 08:22:00-04:00,BMRN,negative
174934.0,Notable Call Options Activity in BioMarin Pharmaceutical,2011-09-28 14:07:00-04:00,BMRN,neutral
174935.0,Notable Call Options Activity in BioMarin Pharmaceutical,2011-09-28 10:29:00-04:00,BMRN,neutral
174936.0,UPDATE: Deutsche Bank Upgrades BioMarin Pharmaceuticals to Buy,2011-09-28 08:35:00-04:00,BMRN,neutral
174937.0,"Deutsche Bank Upgrades BioMarin Pharmaceuticals to Buy, PT Raised to $40",2011-09-28 06:09:00-04:00,BMRN,neutral
174938.0,UPDATE: Piper Jaffray Raises Price Target On BioMarin Pharmaceuticals to $43,2011-09-21 13:10:00-04:00,BMRN,neutral
174939.0,BioMartin Reports $19.6M Notes Converted Into 1.8M Shares,2011-09-12 16:45:00-04:00,BMRN,positive
174940.0,UPDATE: Piper Jaffray Upgrades BioMarin To Overweight,2011-08-10 09:05:00-04:00,BMRN,negative
174941.0,"Piper Jaffray Upgrades BioMarin To Overweight, Raises PT To $33",2011-08-10 07:17:00-04:00,BMRN,negative
174942.0,Stocks to Watch for Monday 8/01/2011: Fresh 52 Week Highs and Lows,2011-07-31 22:55:00-04:00,BMRN,positive
174943.0,Biomarin Pharmaceuticals Reports Q2 EPS $(0.05) vs $(0.11) Est; Revenues $110.63M vs $105.90M Est        ,2011-07-28 16:18:00-04:00,BMRN,neutral
174944.0,Stocks to Watch for Wednesday 7/20/2011: Fresh 52 Week Highs and Lows,2011-07-20 01:51:00-04:00,BMRN,positive
174945.0,BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies,2011-07-14 16:42:00-04:00,BMRN,positive
174946.0,Stocks to Watch for Thursday 7/14/2011: Fresh 52 Week Highs and Lows,2011-07-14 02:29:00-04:00,BMRN,positive
174947.0,BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer for $48.5M,2011-06-23 09:03:00-04:00,BMRN,positive
174948.0,8 Potential Biotech Acquisition Candidates,2011-06-19 14:54:00-04:00,BMRN,neutral
174949.0,T. Boone Pickens' 4 Newest Energy Stock Picks,2011-06-19 14:52:00-04:00,BMRN,positive
174950.0,Pandora: The Latest Sign of Tech Bubble 2.0,2011-06-19 14:50:00-04:00,BMRN,neutral
174951.0,10 Dividend Kings Every Smart Investor Should Own,2011-06-19 14:48:00-04:00,BMRN,positive
174952.0,BioMarin Initiates Phase 3 Trial for Amifampridine Phosphate for the Treatment of LEMS ,2011-06-07 08:02:00-04:00,BMRN,neutral
174953.0,J.P. Morgan Maintains Overweight on BioMarin Pharmaceuticals (BMRN),2011-04-29 07:32:00-04:00,BMRN,negative
174954.0,BioMarin Pharma Reports EPS of $0.14 vs. $(0.10) Estimate; Revenues $109.5M vs. $103.8M Estimate (BMRN),2011-04-28 16:17:00-04:00,BMRN,neutral
174955.0,Global Hunter Maintains Neutral on Myriad Genetics (MYGN),2011-04-07 08:40:00-04:00,BMRN,neutral
174956.0,Myriad Genetics and BioMarin Pharmaceutical Inc. Enter Into Agreement  ,2011-04-06 16:08:00-04:00,BMRN,positive
174957.0,"BioMarin Spending More Than Expected, Duetsche Bank Downgrades To Hold",2011-02-18 09:31:00-05:00,BMRN,neutral
174958.0,"Deutsche Bank Downgrades BioMarin Pharmaceuticals To Hold, PT Remains $27",2011-02-18 08:54:00-05:00,BMRN,neutral
174959.0,Jefferies Raises PT on BioMarin Pharma to $33 (BMRN),2011-02-18 08:46:00-05:00,BMRN,neutral
174960.0,J.P Morgan Comments On BioMarin Pharmaceuticals Following Earnings; Raises PT,2011-02-18 08:27:00-05:00,BMRN,neutral
174961.0,Piper Jaffray Comments On BioMarin Pharmaceutical Following Earnings Results,2011-02-18 07:55:00-05:00,BMRN,neutral
174962.0,Jefferies Raises PT On BioMarin Pharmaceuticals To $33,2011-02-18 07:32:00-05:00,BMRN,neutral
174963.0,JP Morgan Raises PT On BioMarin Pharmaceuticals To $32,2011-02-18 07:25:00-05:00,BMRN,positive
174964.0,BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results: Net Loss of $0.11 Per Share,2011-02-17 16:07:00-05:00,BMRN,neutral
174965.0,Piper Jaffray Neutral On BioMarin Pharmaceutical  (BMRN),2011-02-07 07:25:00-05:00,BMRN,neutral
174966.0,BioMarin Initiates Pivotal Phase 3 Trial for GALNS ,2011-02-01 09:05:00-05:00,BMRN,neutral
174967.0,BioMarin Studies Cure for Cancer  - Analyst Blog,2011-01-12 14:01:00-05:00,BMRN,negative
174968.0,BioMarin Studies Cure for Cancer  - Analyst Blog,2011-01-12 11:45:00-05:00,BMRN,negative
174969.0,BioMarin Initiates Phase 1/2 Trial for BMN 673 ,2011-01-11 11:50:00-05:00,BMRN,neutral
174970.0,Wells Fargo Resumes Coverage On BioMarin With $23-$28 Valuation Range,2010-12-10 10:18:00-05:00,BMRN,positive
174971.0,Boost for BMRN Pipeline - Analyst Blog,2010-12-03 14:30:00-05:00,BMRN,positive
174972.0,Boost for BMRN Pipeline - Analyst Blog,2010-12-03 13:58:00-05:00,BMRN,positive
174973.0,"Benzinga's Top Downgrades (BMRN, ARO, APWR, BUCY)",2010-12-02 09:23:00-05:00,BMRN,positive
174974.0,UBS Downgrades BMRN To Neutral,2010-12-02 08:09:00-05:00,BMRN,neutral
174975.0,Piper Jaffray On BioMarin Pharmaceuticals,2010-12-01 09:20:00-05:00,BMRN,neutral
174976.0,The Daily Long and Short Setup,2010-11-19 10:24:00-05:00,BMRN,neutral
174977.0,In-line Revenues at BioMarin - Analyst Blog,2010-11-02 09:35:00-04:00,BMRN,neutral
174978.0,Biomarin  Pharmaceutical Downgraded to Hold,2010-11-01 12:04:00-04:00,BMRN,neutral
174979.0,BioMarin Announces Third Quarter 2010 Financial Results: EPS of 1.74,2010-10-28 16:19:00-04:00,BMRN,neutral
174980.0,J.P. Morgan Reiterates Overweight On BioMarin (BMRN),2010-10-20 07:31:00-04:00,BMRN,negative
174981.0,BioMarin Announces Program for BMN-111 ,2010-10-19 08:11:00-04:00,BMRN,neutral
174982.0,"Betting on Biotech - Interview with Adam Feuerstein, Senior Columnist and Biotech Analyst of TheStreet.com",2010-10-01 12:46:00-04:00,BMRN,neutral
174983.0,Oppenheimer's Current Biotech Ratings,2010-09-13 10:41:00-04:00,BMRN,neutral
174984.0,Good News for BioMarin's Pipeline - Analyst Blog,2010-08-31 18:12:00-04:00,BMRN,positive
174985.0,BioMarin Evenly Poised - Analyst Blog,2010-08-25 18:46:00-04:00,BMRN,positive
174986.0,BioMarin Acquires Zystor  - Analyst Blog,2010-08-18 16:13:00-04:00,BMRN,neutral
174987.0,BMRN Acquires ZyStor Therapeutics,2010-08-18 08:58:00-04:00,BMRN,neutral
174988.0,"BioMarin to Acquire ZyStor Therapeutics, Inc.",2010-08-17 16:32:00-04:00,BMRN,neutral
174989.0,BioMarin Initiates Phase 3b Study on Subjects with PKU,2010-08-17 09:23:00-04:00,BMRN,neutral
174990.0,"BMRN Rev Misses, Cuts Outlook - Analyst Blog",2010-08-03 15:21:00-04:00,BMRN,negative
174991.0,BioMarin (BMRN) 2Q Results In Line ,2010-08-03 13:07:00-04:00,BMRN,neutral
174992.0,"Benzinga’s Top Pre-Market NASDAQ Losers (SYKE, BMRN, IVAC, ARMH)",2010-08-03 09:06:00-04:00,BMRN,negative
174993.0,BioMarin Pharmaceutical Misses Earnings Estimates (BMRN),2010-08-02 16:21:00-04:00,BMRN,negative
174994.0,"Piper Jaffray Lowers Price Targets In Biotech Complex (BMRN, GENZ, GILD, CELG, ALXN, HGSI)",2010-07-19 11:39:00-04:00,BMRN,negative
174995.0,"John Tepichin Making Great Trades (BMRN, CIEN, NYX, RSH, TIF)",2010-06-09 14:33:00-04:00,BMRN,positive
174996.0,BMRN To Initiate P3 for GALNS in Q4,2010-04-30 14:04:00-04:00,BMRN,neutral
174997.0,Piper Jaffray Raises BioMarin Pharmaceutical (BMRN) Price Target,2010-04-30 09:23:00-04:00,BMRN,neutral
174998.0,"Benzinga’s Volume Movers (TRIT, LULU, GIII, BMRN, CKEC)",2010-03-25 15:07:00-04:00,BMRN,neutral
174999.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,BMRN,positive
175000.0,"Stocks That Created New 52-Week Highs (BGCP, BIIB, BMRN, BJRI, BRCM)",2010-03-10 14:51:00-05:00,BMRN,positive
175001.0,"Top Takeover Targets In The Biotechnology Sector This Year (VRTX, AUXL, CELG, ITMN, GENZ)",2010-03-09 20:09:00-05:00,BMRN,positive
175002.0,BioMarin Pharmaceutical Earnings (BMRN),2010-02-23 19:07:00-05:00,BMRN,neutral
175003.0,"Benzinga’s Top Downgrades (BMRN, AMB, DNB, ARG, HK)",2010-02-08 09:21:00-05:00,BMRN,positive
175004.0,"BioMarin Pharmaceutical, Inc. (BMRN) One Of Top Picks Of 2010",2010-02-05 08:58:00-05:00,BMRN,positive
175005.0,Mid Cap Biotechs May Outperform In 2010,2010-01-15 14:11:00-05:00,BMRN,neutral
175006.0,BioMarin SaysVials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme,2009-11-13 12:02:00-05:00,BMRN,neutral
175007.0,BioMarin Pharmaceutical Inc. Falling On The Genzyme News,2009-11-13 11:57:00-05:00,BMRN,negative
175008.0,"5 Stocks with a Change in Guidance (BMRN, HTZ, LTD)",2009-10-29 06:51:00-04:00,BMRN,neutral
175009.0,BioMarin  (BMRN)  Acquires Aceras BioMedical Portfolio Company ,2009-10-27 08:59:00-04:00,BMRN,neutral
175010.0,"BioMarin Acquires Huxley Pharmaceuticals, Inc.",2009-10-26 16:47:00-04:00,BMRN,neutral
175011.0,"Jim Cramer Would Sell COMS, BMRN, EGLE, HURN, WWE",2009-09-17 15:36:00-04:00,BMRN,neutral
175012.0,"WallStSense.com Fundamental & Technical Coverage of CIEN, AVNR, DRIV, BMRN, CTIC and UMPQ",2009-08-13 06:50:00-04:00,BMRN,neutral
